#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=From the neurobiological basis of comorbid alcohol dependence and depression to psychological treatment strategies: study protocol of a randomized controlled trial Background Alcohol use disorder and depression occur commonly in the community.
1-1	0-4	From	_
1-2	5-8	the	_
1-3	9-24	neurobiological	_
1-4	25-30	basis	_
1-5	31-33	of	_
1-6	34-42	comorbid	_
1-7	43-50	alcohol	_
1-8	51-61	dependence	_
1-9	62-65	and	_
1-10	66-76	depression	_
1-11	77-79	to	_
1-12	80-93	psychological	_
1-13	94-103	treatment	_
1-14	104-114	strategies	_
1-15	115-116	:	_
1-16	117-122	study	_
1-17	123-131	protocol	_
1-18	132-134	of	_
1-19	135-136	a	_
1-20	137-147	randomized	_
1-21	148-158	controlled	_
1-22	159-164	trial	_
1-23	165-175	Background	_
1-24	176-183	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-25	184-187	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-26	188-196	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-27	197-200	and	_
1-28	201-211	depression	_
1-29	212-217	occur	_
1-30	218-226	commonly	_
1-31	227-229	in	_
1-32	230-233	the	_
1-33	234-243	community	_
1-34	244-245	.	_

Text=Even though this high-prevalence comorbidity is associated with poorer posttreatment outcomes and greater utilization of costly treatment services, existing treatment trials often exclude patients with comorbid depressive and alcohol use disorders.
2-1	246-250	Even	_
2-2	251-257	though	_
2-3	258-262	this	_
2-4	263-278	high-prevalence	_
2-5	279-290	comorbidity	_
2-6	291-293	is	_
2-7	294-304	associated	_
2-8	305-309	with	_
2-9	310-316	poorer	_
2-10	317-330	posttreatment	_
2-11	331-339	outcomes	_
2-12	340-343	and	_
2-13	344-351	greater	_
2-14	352-363	utilization	_
2-15	364-366	of	_
2-16	367-373	costly	_
2-17	374-383	treatment	_
2-18	384-392	services	_
2-19	393-394	,	_
2-20	395-403	existing	_
2-21	404-413	treatment	_
2-22	414-420	trials	_
2-23	421-426	often	_
2-24	427-434	exclude	_
2-25	435-443	patients	_
2-26	444-448	with	_
2-27	449-457	comorbid	_
2-28	458-468	depressive	_
2-29	469-472	and	_
2-30	473-480	alcohol	_
2-31	481-484	use	_
2-32	485-494	disorders	_
2-33	495-496	.	_

Text=Past research suggests that symptoms such as craving and anhedonia might be associated with alterations within the reward circuit, while emotion regulation deficits are related to disruptions within the default mode network.
3-1	497-501	Past	_
3-2	502-510	research	_
3-3	511-519	suggests	_
3-4	520-524	that	_
3-5	525-533	symptoms	_
3-6	534-538	such	_
3-7	539-541	as	_
3-8	542-549	craving	_
3-9	550-553	and	_
3-10	554-563	anhedonia	_
3-11	564-569	might	_
3-12	570-572	be	_
3-13	573-583	associated	_
3-14	584-588	with	_
3-15	589-600	alterations	_
3-16	601-607	within	_
3-17	608-611	the	_
3-18	612-618	reward	_
3-19	619-626	circuit	_
3-20	627-628	,	_
3-21	629-634	while	_
3-22	635-642	emotion	_
3-23	643-653	regulation	_
3-24	654-662	deficits	_
3-25	663-666	are	_
3-26	667-674	related	_
3-27	675-677	to	_
3-28	678-689	disruptions	_
3-29	690-696	within	_
3-30	697-700	the	_
3-31	701-708	default	_
3-32	709-713	mode	_
3-33	714-721	network	_
3-34	722-723	.	_

Text=The aim of this clinical neuroimaging study is to transfer previous research about the reward circuit and default mode network underlying alcohol use disorder and depression to achieve a better understanding of neural signatures characterizing their comorbidity.
4-1	724-727	The	_
4-2	728-731	aim	_
4-3	732-734	of	_
4-4	735-739	this	_
4-5	740-748	clinical	_
4-6	749-761	neuroimaging	_
4-7	762-767	study	_
4-8	768-770	is	_
4-9	771-773	to	_
4-10	774-782	transfer	_
4-11	783-791	previous	_
4-12	792-800	research	_
4-13	801-806	about	_
4-14	807-810	the	_
4-15	811-817	reward	_
4-16	818-825	circuit	_
4-17	826-829	and	_
4-18	830-837	default	_
4-19	838-842	mode	_
4-20	843-850	network	_
4-21	851-861	underlying	_
4-22	862-869	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
4-23	870-873	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
4-24	874-882	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
4-25	883-886	and	_
4-26	887-897	depression	_
4-27	898-900	to	_
4-28	901-908	achieve	_
4-29	909-910	a	_
4-30	911-917	better	_
4-31	918-931	understanding	_
4-32	932-934	of	_
4-33	935-941	neural	_
4-34	942-952	signatures	_
4-35	953-967	characterizing	_
4-36	968-973	their	_
4-37	974-985	comorbidity	_
4-38	986-987	.	_

Text=In addition, the neurobiological results will be used to test whether two psychotherapeutic intervention programs, mindfulness-based training and behavioral activation training, are able to positively influence the identified pathomechanisms.
5-1	988-990	In	_
5-2	991-999	addition	_
5-3	1000-1001	,	_
5-4	1002-1005	the	_
5-5	1006-1021	neurobiological	_
5-6	1022-1029	results	_
5-7	1030-1034	will	_
5-8	1035-1037	be	_
5-9	1038-1042	used	_
5-10	1043-1045	to	_
5-11	1046-1050	test	_
5-12	1051-1058	whether	_
5-13	1059-1062	two	_
5-14	1063-1080	psychotherapeutic	_
5-15	1081-1093	intervention	_
5-16	1094-1102	programs	_
5-17	1103-1104	,	_
5-18	1105-1122	mindfulness-based	_
5-19	1123-1131	training	_
5-20	1132-1135	and	_
5-21	1136-1146	behavioral	_
5-22	1147-1157	activation	_
5-23	1158-1166	training	_
5-24	1167-1168	,	_
5-25	1169-1172	are	_
5-26	1173-1177	able	_
5-27	1178-1180	to	_
5-28	1181-1191	positively	_
5-29	1192-1201	influence	_
5-30	1202-1205	the	_
5-31	1206-1216	identified	_
5-32	1217-1232	pathomechanisms	_
5-33	1233-1234	.	_

Text=Methods By means of functional magnetic resonance imaging (fMRI), 60 comorbid alcohol dependent and depressed patients are compared to 30 patients with depression only, 30 patients with alcohol use disorder only and 30 healthy control participants.
6-1	1235-1242	Methods	_
6-2	1243-1245	By	_
6-3	1246-1251	means	_
6-4	1252-1254	of	_
6-5	1255-1265	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-6	1266-1274	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-7	1275-1284	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-8	1285-1292	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-9	1293-1294	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-10	1295-1299	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-11	1300-1301	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-12	1302-1303	,	_
6-13	1304-1306	60	_
6-14	1307-1315	comorbid	_
6-15	1316-1323	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
6-16	1324-1333	dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
6-17	1334-1337	and	_
6-18	1338-1347	depressed	_
6-19	1348-1356	patients	_
6-20	1357-1360	are	_
6-21	1361-1369	compared	_
6-22	1370-1372	to	_
6-23	1373-1375	30	_
6-24	1376-1384	patients	http://maven.renci.org/NeuroBridge/neurobridge#Depression
6-25	1385-1389	with	http://maven.renci.org/NeuroBridge/neurobridge#Depression
6-26	1390-1400	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
6-27	1401-1405	only	_
6-28	1406-1407	,	_
6-29	1408-1410	30	_
6-30	1411-1419	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-31	1420-1424	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-32	1425-1432	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
6-33	1433-1436	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
6-34	1437-1445	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
6-35	1446-1450	only	_
6-36	1451-1454	and	_
6-37	1455-1457	30	_
6-38	1458-1465	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-39	1466-1473	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-40	1474-1486	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-41	1487-1488	.	_

Text=Comorbid patients are randomized to either receive a behavioral activation or mindfulness based training and asked to participate in a second fMRI session and 3 month follow-up assessment.
7-1	1489-1497	Comorbid	_
7-2	1498-1506	patients	_
7-3	1507-1510	are	_
7-4	1511-1521	randomized	_
7-5	1522-1524	to	_
7-6	1525-1531	either	_
7-7	1532-1539	receive	_
7-8	1540-1541	a	_
7-9	1542-1552	behavioral	_
7-10	1553-1563	activation	_
7-11	1564-1566	or	_
7-12	1567-1578	mindfulness	_
7-13	1579-1584	based	_
7-14	1585-1593	training	_
7-15	1594-1597	and	_
7-16	1598-1603	asked	_
7-17	1604-1606	to	_
7-18	1607-1618	participate	_
7-19	1619-1621	in	_
7-20	1622-1623	a	_
7-21	1624-1630	second	_
7-22	1631-1635	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
7-23	1636-1643	session	_
7-24	1644-1647	and	_
7-25	1648-1649	3	_
7-26	1650-1655	month	_
7-27	1656-1665	follow-up	_
7-28	1666-1676	assessment	_
7-29	1677-1678	.	_

Text=Thereby, we plan to explore whether these brief group psychotherapeutic intervention programs are able to positively influence the identified neurobiological pathomechanisms.
8-1	1679-1686	Thereby	_
8-2	1687-1688	,	_
8-3	1689-1691	we	_
8-4	1692-1696	plan	_
8-5	1697-1699	to	_
8-6	1700-1707	explore	_
8-7	1708-1715	whether	_
8-8	1716-1721	these	_
8-9	1722-1727	brief	_
8-10	1728-1733	group	_
8-11	1734-1751	psychotherapeutic	_
8-12	1752-1764	intervention	_
8-13	1765-1773	programs	_
8-14	1774-1777	are	_
8-15	1778-1782	able	_
8-16	1783-1785	to	_
8-17	1786-1796	positively	_
8-18	1797-1806	influence	_
8-19	1807-1810	the	_
8-20	1811-1821	identified	_
8-21	1822-1837	neurobiological	_
8-22	1838-1853	pathomechanisms	_
8-23	1854-1855	.	_

Text=The primary outcomes are reward and default mode network activity and connectivity evoked by paradigms measuring different facets of reward and emotion processing.
9-1	1856-1859	The	_
9-2	1860-1867	primary	_
9-3	1868-1876	outcomes	_
9-4	1877-1880	are	_
9-5	1881-1887	reward	_
9-6	1888-1891	and	_
9-7	1892-1899	default	_
9-8	1900-1904	mode	_
9-9	1905-1912	network	_
9-10	1913-1921	activity	_
9-11	1922-1925	and	_
9-12	1926-1938	connectivity	_
9-13	1939-1945	evoked	_
9-14	1946-1948	by	_
9-15	1949-1958	paradigms	_
9-16	1959-1968	measuring	_
9-17	1969-1978	different	_
9-18	1979-1985	facets	_
9-19	1986-1988	of	_
9-20	1989-1995	reward	_
9-21	1996-1999	and	_
9-22	2000-2007	emotion	_
9-23	2008-2018	processing	_
9-24	2019-2020	.	_

Text=Secondary outcome measures include craving and depression scores, as well as relapse rates.
10-1	2021-2030	Secondary	_
10-2	2031-2038	outcome	_
10-3	2039-2047	measures	_
10-4	2048-2055	include	_
10-5	2056-2063	craving	_
10-6	2064-2067	and	_
10-7	2068-2078	depression	_
10-8	2079-2085	scores	_
10-9	2086-2087	,	_
10-10	2088-2090	as	_
10-11	2091-2095	well	_
10-12	2096-2098	as	_
10-13	2099-2106	relapse	_
10-14	2107-2112	rates	_
10-15	2113-2114	.	_

Text=Predictors include participants ’ characteristics, personality traits and indicators of mental health.
11-1	2115-2125	Predictors	_
11-2	2126-2133	include	_
11-3	2134-2146	participants	_
11-4	2147-2148	’	_
11-5	2149-2164	characteristics	_
11-6	2165-2166	,	_
11-7	2167-2178	personality	_
11-8	2179-2185	traits	_
11-9	2186-2189	and	_
11-10	2190-2200	indicators	_
11-11	2201-2203	of	_
11-12	2204-2210	mental	_
11-13	2211-2217	health	_
11-14	2218-2219	.	_

Text=Discussion The objective of the project is to identify common and/or distinct neural signatures underlying the comorbidity of alcohol dependence and depression.
12-1	2220-2230	Discussion	_
12-2	2231-2234	The	_
12-3	2235-2244	objective	_
12-4	2245-2247	of	_
12-5	2248-2251	the	_
12-6	2252-2259	project	_
12-7	2260-2262	is	_
12-8	2263-2265	to	_
12-9	2266-2274	identify	_
12-10	2275-2281	common	_
12-11	2282-2288	and/or	_
12-12	2289-2297	distinct	_
12-13	2298-2304	neural	_
12-14	2305-2315	signatures	_
12-15	2316-2326	underlying	_
12-16	2327-2330	the	_
12-17	2331-2342	comorbidity	_
12-18	2343-2345	of	_
12-19	2346-2353	alcohol	_
12-20	2354-2364	dependence	_
12-21	2365-2368	and	_
12-22	2369-2379	depression	_
12-23	2380-2381	.	_

Text=If the neurobiological understanding of alcohol addiction and depression is improved, this could potentially serve as a key predictor of treatment response to specific types of behavioral or mindfulness therapies hypothesized to alter reward and resting state systems.
13-1	2382-2384	If	_
13-2	2385-2388	the	_
13-3	2389-2404	neurobiological	_
13-4	2405-2418	understanding	_
13-5	2419-2421	of	_
13-6	2422-2429	alcohol	_
13-7	2430-2439	addiction	_
13-8	2440-2443	and	_
13-9	2444-2454	depression	_
13-10	2455-2457	is	_
13-11	2458-2466	improved	_
13-12	2467-2468	,	_
13-13	2469-2473	this	_
13-14	2474-2479	could	_
13-15	2480-2491	potentially	_
13-16	2492-2497	serve	_
13-17	2498-2500	as	_
13-18	2501-2502	a	_
13-19	2503-2506	key	_
13-20	2507-2516	predictor	_
13-21	2517-2519	of	_
13-22	2520-2529	treatment	_
13-23	2530-2538	response	_
13-24	2539-2541	to	_
13-25	2542-2550	specific	_
13-26	2551-2556	types	_
13-27	2557-2559	of	_
13-28	2560-2570	behavioral	_
13-29	2571-2573	or	_
13-30	2574-2585	mindfulness	_
13-31	2586-2595	therapies	_
13-32	2596-2608	hypothesized	_
13-33	2609-2611	to	_
13-34	2612-2617	alter	_
13-35	2618-2624	reward	_
13-36	2625-2628	and	_
13-37	2629-2636	resting	_
13-38	2637-2642	state	_
13-39	2643-2650	systems	_
13-40	2651-2652	.	_

Text=Trial registration German Clinical Trial Register DRKS00010249.
14-1	2653-2658	Trial	_
14-2	2659-2671	registration	_
14-3	2672-2678	German	_
14-4	2679-2687	Clinical	_
14-5	2688-2693	Trial	_
14-6	2694-2702	Register	_
14-7	2703-2715	DRKS00010249	_
14-8	2716-2717	.	_

Text=The trial was registered January 23th 2017.
15-1	2718-2721	The	_
15-2	2722-2727	trial	_
15-3	2728-2731	was	_
15-4	2732-2742	registered	_
15-5	2743-2750	January	_
15-6	2751-2755	23th	_
15-7	2756-2760	2017	_
15-8	2761-2762	.	_

Text=Neurobiological informed treatment interventions for comorbidity: Psychotherapy The ultimate goal of a better understanding of the neurobiological underpinnings is to develop preventive and more effective treatment strategies.
16-1	2763-2778	Neurobiological	_
16-2	2779-2787	informed	_
16-3	2788-2797	treatment	_
16-4	2798-2811	interventions	_
16-5	2812-2815	for	_
16-6	2816-2827	comorbidity	_
16-7	2828-2829	:	_
16-8	2830-2843	Psychotherapy	_
16-9	2844-2847	The	_
16-10	2848-2856	ultimate	_
16-11	2857-2861	goal	_
16-12	2862-2864	of	_
16-13	2865-2866	a	_
16-14	2867-2873	better	_
16-15	2874-2887	understanding	_
16-16	2888-2890	of	_
16-17	2891-2894	the	_
16-18	2895-2910	neurobiological	_
16-19	2911-2924	underpinnings	_
16-20	2925-2927	is	_
16-21	2928-2930	to	_
16-22	2931-2938	develop	_
16-23	2939-2949	preventive	_
16-24	2950-2953	and	_
16-25	2954-2958	more	_
16-26	2959-2968	effective	_
16-27	2969-2978	treatment	_
16-28	2979-2989	strategies	_
16-29	2990-2991	.	_

Text=Compared to antidepressant or anticraving medication, less research has examined functional neural responses after psychotherapy.
17-1	2992-3000	Compared	_
17-2	3001-3003	to	_
17-3	3004-3018	antidepressant	_
17-4	3019-3021	or	_
17-5	3022-3033	anticraving	_
17-6	3034-3044	medication	_
17-7	3045-3046	,	_
17-8	3047-3051	less	_
17-9	3052-3060	research	_
17-10	3061-3064	has	_
17-11	3065-3073	examined	_
17-12	3074-3084	functional	_
17-13	3085-3091	neural	_
17-14	3092-3101	responses	_
17-15	3102-3107	after	_
17-16	3108-3121	psychotherapy	_
17-17	3122-3123	.	_

Text=Available data suggest that psychotherapy predicts metabolic changes in reward, cingulate and frontal cortices in alcohol dependence and depression.
18-1	3124-3133	Available	_
18-2	3134-3138	data	_
18-3	3139-3146	suggest	_
18-4	3147-3151	that	_
18-5	3152-3165	psychotherapy	_
18-6	3166-3174	predicts	_
18-7	3175-3184	metabolic	_
18-8	3185-3192	changes	_
18-9	3193-3195	in	_
18-10	3196-3202	reward	_
18-11	3203-3204	,	_
18-12	3205-3214	cingulate	_
18-13	3215-3218	and	_
18-14	3219-3226	frontal	_
18-15	3227-3235	cortices	_
18-16	3236-3238	in	_
18-17	3239-3246	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
18-18	3247-3257	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
18-19	3258-3261	and	_
18-20	3262-3272	depression	_
18-21	3273-3274	.	_

Text=To our knowledge, only a few studies evaluated the effects of a specific psychotherapeutic intervention like the brief Behavioral Activation Treatment (BAT) for depression on brain activation.
19-1	3275-3277	To	_
19-2	3278-3281	our	_
19-3	3282-3291	knowledge	_
19-4	3292-3293	,	_
19-5	3294-3298	only	_
19-6	3299-3300	a	_
19-7	3301-3304	few	_
19-8	3305-3312	studies	_
19-9	3313-3322	evaluated	_
19-10	3323-3326	the	_
19-11	3327-3334	effects	_
19-12	3335-3337	of	_
19-13	3338-3339	a	_
19-14	3340-3348	specific	_
19-15	3349-3366	psychotherapeutic	_
19-16	3367-3379	intervention	_
19-17	3380-3384	like	_
19-18	3385-3388	the	_
19-19	3389-3394	brief	_
19-20	3395-3405	Behavioral	_
19-21	3406-3416	Activation	_
19-22	3417-3426	Treatment	_
19-23	3427-3428	(	_
19-24	3429-3432	BAT	_
19-25	3433-3434	)	_
19-26	3435-3438	for	_
19-27	3439-3449	depression	_
19-28	3450-3452	on	_
19-29	3453-3458	brain	_
19-30	3459-3469	activation	_
19-31	3470-3471	.	_

Text=Dichter and colleagues report functional changes in reward associated structures including the dorsal striatum during reward anticipation after a BAT intervention but did not include a depressed control group.
20-1	3472-3479	Dichter	_
20-2	3480-3483	and	_
20-3	3484-3494	colleagues	_
20-4	3495-3501	report	_
20-5	3502-3512	functional	_
20-6	3513-3520	changes	_
20-7	3521-3523	in	_
20-8	3524-3530	reward	_
20-9	3531-3541	associated	_
20-10	3542-3552	structures	_
20-11	3553-3562	including	_
20-12	3563-3566	the	_
20-13	3567-3573	dorsal	_
20-14	3574-3582	striatum	_
20-15	3583-3589	during	_
20-16	3590-3596	reward	_
20-17	3597-3609	anticipation	_
20-18	3610-3615	after	_
20-19	3616-3617	a	_
20-20	3618-3621	BAT	_
20-21	3622-3634	intervention	_
20-22	3635-3638	but	_
20-23	3639-3642	did	_
20-24	3643-3646	not	_
20-25	3647-3654	include	_
20-26	3655-3656	a	_
20-27	3657-3666	depressed	_
20-28	3667-3674	control	_
20-29	3675-3680	group	_
20-30	3681-3682	.	_

Text=Looking on the DMN connectivity, Crowther and colleagues found that the response to BAT in depressed patients was predicted by pretreatment connectivity of the right insula with the right middle temporal gyrus and the left intraparietal sulcus.
21-1	3683-3690	Looking	_
21-2	3691-3693	on	_
21-3	3694-3697	the	_
21-4	3698-3701	DMN	_
21-5	3702-3714	connectivity	_
21-6	3715-3716	,	_
21-7	3717-3725	Crowther	_
21-8	3726-3729	and	_
21-9	3730-3740	colleagues	_
21-10	3741-3746	found	_
21-11	3747-3751	that	_
21-12	3752-3755	the	_
21-13	3756-3764	response	_
21-14	3765-3767	to	_
21-15	3768-3771	BAT	http://maven.renci.org/NeuroBridge/neurobridge#FrontalAssessmentBattery
21-16	3772-3774	in	_
21-17	3775-3784	depressed	http://maven.renci.org/NeuroBridge/neurobridge#Depression
21-18	3785-3793	patients	http://maven.renci.org/NeuroBridge/neurobridge#Depression
21-19	3794-3797	was	_
21-20	3798-3807	predicted	_
21-21	3808-3810	by	_
21-22	3811-3823	pretreatment	_
21-23	3824-3836	connectivity	_
21-24	3837-3839	of	_
21-25	3840-3843	the	_
21-26	3844-3849	right	_
21-27	3850-3856	insula	_
21-28	3857-3861	with	_
21-29	3862-3865	the	_
21-30	3866-3871	right	_
21-31	3872-3878	middle	_
21-32	3879-3887	temporal	_
21-33	3888-3893	gyrus	_
21-34	3894-3897	and	_
21-35	3898-3901	the	_
21-36	3902-3906	left	_
21-37	3907-3920	intraparietal	_
21-38	3921-3927	sulcus	_
21-39	3928-3929	.	_

Text=Another psychotherapeutic intervention with potential effects on resting state networks is mindfulness based therapy (MBT).
22-1	3930-3937	Another	_
22-2	3938-3955	psychotherapeutic	_
22-3	3956-3968	intervention	_
22-4	3969-3973	with	_
22-5	3974-3983	potential	_
22-6	3984-3991	effects	_
22-7	3992-3994	on	_
22-8	3995-4002	resting	_
22-9	4003-4008	state	_
22-10	4009-4017	networks	_
22-11	4018-4020	is	_
22-12	4021-4032	mindfulness	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalDisease
22-13	4033-4038	based	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalDisease
22-14	4039-4046	therapy	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalDisease
22-15	4047-4048	(	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalDisease
22-16	4049-4052	MBT	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalDisease
22-17	4053-4054	)	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalDisease
22-18	4055-4056	.	_

Text=MBT is a meditation practice that is recently receiving growing attention for its potential clinical applications in the context of alcohol dependence and depression.
23-1	4057-4060	MBT	_
23-2	4061-4063	is	_
23-3	4064-4065	a	_
23-4	4066-4076	meditation	_
23-5	4077-4085	practice	_
23-6	4086-4090	that	_
23-7	4091-4093	is	_
23-8	4094-4102	recently	_
23-9	4103-4112	receiving	_
23-10	4113-4120	growing	_
23-11	4121-4130	attention	_
23-12	4131-4134	for	_
23-13	4135-4138	its	_
23-14	4139-4148	potential	_
23-15	4149-4157	clinical	_
23-16	4158-4170	applications	_
23-17	4171-4173	in	_
23-18	4174-4177	the	_
23-19	4178-4185	context	_
23-20	4186-4188	of	_
23-21	4189-4196	alcohol	_
23-22	4197-4207	dependence	_
23-23	4208-4211	and	_
23-24	4212-4222	depression	_
23-25	4223-4224	.	_

Text=Neuroimaging studies showed that long-term meditators showed increased activation of prefrontal areas during meditation as compared with a rest condition or with matched control subjects naïve to meditation practice.
24-1	4225-4237	Neuroimaging	_
24-2	4238-4245	studies	_
24-3	4246-4252	showed	_
24-4	4253-4257	that	_
24-5	4258-4267	long-term	_
24-6	4268-4278	meditators	_
24-7	4279-4285	showed	_
24-8	4286-4295	increased	_
24-9	4296-4306	activation	_
24-10	4307-4309	of	_
24-11	4310-4320	prefrontal	_
24-12	4321-4326	areas	_
24-13	4327-4333	during	_
24-14	4334-4344	meditation	_
24-15	4345-4347	as	_
24-16	4348-4356	compared	_
24-17	4357-4361	with	_
24-18	4362-4363	a	_
24-19	4364-4368	rest	_
24-20	4369-4378	condition	_
24-21	4379-4381	or	_
24-22	4382-4386	with	_
24-23	4387-4394	matched	_
24-24	4395-4402	control	_
24-25	4403-4411	subjects	_
24-26	4412-4417	naïve	_
24-27	4418-4420	to	_
24-28	4421-4431	meditation	_
24-29	4432-4440	practice	_
24-30	4441-4442	.	_

Text=In summary, dysfunctions in the reward circuit, as well as DMN have been identified as key domains underlying alcohol dependence and depression.
25-1	4443-4445	In	_
25-2	4446-4453	summary	_
25-3	4454-4455	,	_
25-4	4456-4468	dysfunctions	_
25-5	4469-4471	in	_
25-6	4472-4475	the	_
25-7	4476-4482	reward	_
25-8	4483-4490	circuit	_
25-9	4491-4492	,	_
25-10	4493-4495	as	_
25-11	4496-4500	well	_
25-12	4501-4503	as	_
25-13	4504-4507	DMN	_
25-14	4508-4512	have	_
25-15	4513-4517	been	_
25-16	4518-4528	identified	_
25-17	4529-4531	as	_
25-18	4532-4535	key	_
25-19	4536-4543	domains	_
25-20	4544-4554	underlying	_
25-21	4555-4562	alcohol	_
25-22	4563-4573	dependence	_
25-23	4574-4577	and	_
25-24	4578-4588	depression	_
25-25	4589-4590	.	_

Text=We assume that these mechanisms also characterize the neurobiological underpinning of their comorbidity.
26-1	4591-4593	We	_
26-2	4594-4600	assume	_
26-3	4601-4605	that	_
26-4	4606-4611	these	_
26-5	4612-4622	mechanisms	_
26-6	4623-4627	also	_
26-7	4628-4640	characterize	_
26-8	4641-4644	the	_
26-9	4645-4660	neurobiological	_
26-10	4661-4673	underpinning	_
26-11	4674-4676	of	_
26-12	4677-4682	their	_
26-13	4683-4694	comorbidity	_
26-14	4695-4696	.	_

Text=Thereby, the identification of neural risk factors associated with their co-occurrence might help in understanding the pathophysiological mechanisms leading to their onset and course.
27-1	4697-4704	Thereby	_
27-2	4705-4706	,	_
27-3	4707-4710	the	_
27-4	4711-4725	identification	_
27-5	4726-4728	of	_
27-6	4729-4735	neural	_
27-7	4736-4740	risk	_
27-8	4741-4748	factors	_
27-9	4749-4759	associated	_
27-10	4760-4764	with	_
27-11	4765-4770	their	_
27-12	4771-4784	co-occurrence	_
27-13	4785-4790	might	_
27-14	4791-4795	help	_
27-15	4796-4798	in	_
27-16	4799-4812	understanding	_
27-17	4813-4816	the	_
27-18	4817-4835	pathophysiological	_
27-19	4836-4846	mechanisms	_
27-20	4847-4854	leading	_
27-21	4855-4857	to	_
27-22	4858-4863	their	_
27-23	4864-4869	onset	_
27-24	4870-4873	and	_
27-25	4874-4880	course	_
27-26	4881-4882	.	_

Text=The overall goal of improving our understanding of neurobiological mechanisms is to improve treatment.
28-1	4883-4886	The	_
28-2	4887-4894	overall	_
28-3	4895-4899	goal	_
28-4	4900-4902	of	_
28-5	4903-4912	improving	_
28-6	4913-4916	our	_
28-7	4917-4930	understanding	_
28-8	4931-4933	of	_
28-9	4934-4949	neurobiological	_
28-10	4950-4960	mechanisms	_
28-11	4961-4963	is	_
28-12	4964-4966	to	_
28-13	4967-4974	improve	_
28-14	4975-4984	treatment	_
28-15	4985-4986	.	_

Text=If the neurobiological understanding of alcohol dependence and depression is improved, this could potentially serve as a key predictor of treatment response to specific types of behavioral (BAT) or mindfulness (e.g.
29-1	4987-4989	If	_
29-2	4990-4993	the	_
29-3	4994-5009	neurobiological	_
29-4	5010-5023	understanding	_
29-5	5024-5026	of	_
29-6	5027-5034	alcohol	_
29-7	5035-5045	dependence	_
29-8	5046-5049	and	_
29-9	5050-5060	depression	_
29-10	5061-5063	is	_
29-11	5064-5072	improved	_
29-12	5073-5074	,	_
29-13	5075-5079	this	_
29-14	5080-5085	could	_
29-15	5086-5097	potentially	_
29-16	5098-5103	serve	_
29-17	5104-5106	as	_
29-18	5107-5108	a	_
29-19	5109-5112	key	_
29-20	5113-5122	predictor	_
29-21	5123-5125	of	_
29-22	5126-5135	treatment	_
29-23	5136-5144	response	_
29-24	5145-5147	to	_
29-25	5148-5156	specific	_
29-26	5157-5162	types	_
29-27	5163-5165	of	_
29-28	5166-5176	behavioral	_
29-29	5177-5178	(	_
29-30	5179-5182	BAT	_
29-31	5183-5184	)	_
29-32	5185-5187	or	_
29-33	5188-5199	mindfulness	_
29-34	5200-5201	(	_
29-35	5202-5205	e.g	_
29-36	5206-5207	.	_

Text=MBT) therapies shown to alter reward and resting state systems.
30-1	5208-5211	MBT	_
30-2	5212-5213	)	_
30-3	5214-5223	therapies	_
30-4	5224-5229	shown	_
30-5	5230-5232	to	_
30-6	5233-5238	alter	_
30-7	5239-5245	reward	_
30-8	5246-5249	and	_
30-9	5250-5257	resting	_
30-10	5258-5263	state	_
30-11	5264-5271	systems	_
30-12	5272-5273	.	_

Text=Methods Study design In this randomized-controlled trial, comorbid alcohol dependent and depressed patients will be compared to depressed only, alcohol dependent only and healthy control participants.
31-1	5274-5281	Methods	_
31-2	5282-5287	Study	_
31-3	5288-5294	design	_
31-4	5295-5297	In	_
31-5	5298-5302	this	_
31-6	5303-5324	randomized-controlled	_
31-7	5325-5330	trial	_
31-8	5331-5332	,	_
31-9	5333-5341	comorbid	_
31-10	5342-5349	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
31-11	5350-5359	dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
31-12	5360-5363	and	_
31-13	5364-5373	depressed	http://maven.renci.org/NeuroBridge/neurobridge#DepressiveDisorder
31-14	5374-5382	patients	_
31-15	5383-5387	will	_
31-16	5388-5390	be	_
31-17	5391-5399	compared	_
31-18	5400-5402	to	_
31-19	5403-5412	depressed	_
31-20	5413-5417	only	_
31-21	5418-5419	,	_
31-22	5420-5427	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
31-23	5428-5437	dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
31-24	5438-5442	only	_
31-25	5443-5446	and	_
31-26	5447-5454	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
31-27	5455-5462	control	_
31-28	5463-5475	participants	_
31-29	5476-5477	.	_

Text=All participants are screened and after examination of inclusion and exclusion criteria admitted to the study.
32-1	5478-5481	All	_
32-2	5482-5494	participants	_
32-3	5495-5498	are	_
32-4	5499-5507	screened	_
32-5	5508-5511	and	_
32-6	5512-5517	after	_
32-7	5518-5529	examination	_
32-8	5530-5532	of	_
32-9	5533-5542	inclusion	_
32-10	5543-5546	and	_
32-11	5547-5556	exclusion	_
32-12	5557-5565	criteria	_
32-13	5566-5574	admitted	_
32-14	5575-5577	to	_
32-15	5578-5581	the	_
32-16	5582-5587	study	_
32-17	5588-5589	.	_

Text=All participants will receive a baseline fMRI session (T1).
33-1	5590-5593	All	_
33-2	5594-5606	participants	_
33-3	5607-5611	will	_
33-4	5612-5619	receive	_
33-5	5620-5621	a	_
33-6	5622-5630	baseline	_
33-7	5631-5635	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
33-8	5636-5643	session	_
33-9	5644-5645	(	_
33-10	5646-5648	T1	_
33-11	5649-5650	)	_
33-12	5651-5652	.	_

Text=Subsequently, only comorbid alcohol dependent and depressed patients will be randomized to either receiving group BAT or MBT training for 6 weeks.
34-1	5653-5665	Subsequently	_
34-2	5666-5667	,	_
34-3	5668-5672	only	_
34-4	5673-5681	comorbid	_
34-5	5682-5689	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
34-6	5690-5699	dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
34-7	5700-5703	and	_
34-8	5704-5713	depressed	http://maven.renci.org/NeuroBridge/neurobridge#Depression
34-9	5714-5722	patients	http://maven.renci.org/NeuroBridge/neurobridge#Depression
34-10	5723-5727	will	_
34-11	5728-5730	be	_
34-12	5731-5741	randomized	_
34-13	5742-5744	to	_
34-14	5745-5751	either	_
34-15	5752-5761	receiving	_
34-16	5762-5767	group	_
34-17	5768-5771	BAT	_
34-18	5772-5774	or	_
34-19	5775-5778	MBT	http://maven.renci.org/NeuroBridge/neurobridge#Thing
34-20	5779-5787	training	_
34-21	5788-5791	for	_
34-22	5792-5793	6	_
34-23	5794-5799	weeks	_
34-24	5800-5801	.	_

Text=Afterwards comorbid patients will receive an outcome fMRI session (T2) and will be contacted after three months for a catamnestic exploration.
35-1	5802-5812	Afterwards	_
35-2	5813-5821	comorbid	_
35-3	5822-5830	patients	_
35-4	5831-5835	will	_
35-5	5836-5843	receive	_
35-6	5844-5846	an	_
35-7	5847-5854	outcome	_
35-8	5855-5859	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
35-9	5860-5867	session	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
35-10	5868-5869	(	_
35-11	5870-5872	T2	http://maven.renci.org/NeuroBridge/neurobridge#Thing
35-12	5873-5874	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
35-13	5875-5878	and	_
35-14	5879-5883	will	_
35-15	5884-5886	be	_
35-16	5887-5896	contacted	_
35-17	5897-5902	after	_
35-18	5903-5908	three	_
35-19	5909-5915	months	_
35-20	5916-5919	for	_
35-21	5920-5921	a	_
35-22	5922-5933	catamnestic	_
35-23	5934-5945	exploration	_
35-24	5946-5947	.	_

Text=For a flow chart of the study design please refer to Fig.
36-1	5948-5951	For	_
36-2	5952-5953	a	_
36-3	5954-5958	flow	_
36-4	5959-5964	chart	_
36-5	5965-5967	of	_
36-6	5968-5971	the	_
36-7	5972-5977	study	_
36-8	5978-5984	design	_
36-9	5985-5991	please	_
36-10	5992-5997	refer	_
36-11	5998-6000	to	_
36-12	6001-6004	Fig	_
36-13	6005-6006	.	_

Text=1.
37-1	6007-6008	1	_
37-2	6009-6010	.	_

Text=Participants Sixty comorbid alcohol dependent and depressed patients, 30 alcohol dependent only and 30 depressed only patients will be included for T1 assessment.
38-1	6011-6023	Participants	_
38-2	6024-6029	Sixty	_
38-3	6030-6038	comorbid	_
38-4	6039-6046	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
38-5	6047-6056	dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
38-6	6057-6060	and	_
38-7	6061-6070	depressed	http://maven.renci.org/NeuroBridge/neurobridge#Depression
38-8	6071-6079	patients	http://maven.renci.org/NeuroBridge/neurobridge#Depression
38-9	6080-6081	,	_
38-10	6082-6084	30	_
38-11	6085-6092	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
38-12	6093-6102	dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
38-13	6103-6107	only	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
38-14	6108-6111	and	_
38-15	6112-6114	30	_
38-16	6115-6124	depressed	http://maven.renci.org/NeuroBridge/neurobridge#Depression
38-17	6125-6129	only	http://maven.renci.org/NeuroBridge/neurobridge#Depression
38-18	6130-6138	patients	http://maven.renci.org/NeuroBridge/neurobridge#Depression
38-19	6139-6143	will	_
38-20	6144-6146	be	_
38-21	6147-6155	included	_
38-22	6156-6159	for	_
38-23	6160-6162	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-24	6163-6173	assessment	_
38-25	6174-6175	.	_

Text=Further, 30 healthy control participants (matched according to age, gender and educational level) will be recruited.
39-1	6176-6183	Further	_
39-2	6184-6185	,	_
39-3	6186-6188	30	_
39-4	6189-6196	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
39-5	6197-6204	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
39-6	6205-6217	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
39-7	6218-6219	(	_
39-8	6220-6227	matched	_
39-9	6228-6237	according	_
39-10	6238-6240	to	_
39-11	6241-6244	age	_
39-12	6245-6246	,	_
39-13	6247-6253	gender	_
39-14	6254-6257	and	_
39-15	6258-6269	educational	_
39-16	6270-6275	level	_
39-17	6276-6277	)	_
39-18	6278-6282	will	_
39-19	6283-6285	be	_
39-20	6286-6295	recruited	_
39-21	6296-6297	.	_

Text=Eligibility All participants will be 1) aged between 18 and 65 years, 2) have to provide informed consent, 3) be right-handed, 4) show an appropriate comprehension of the German language and 5) must be able to accurately watch visual stimuli in the scanner environment.
40-1	6298-6309	Eligibility	_
40-2	6310-6313	All	_
40-3	6314-6326	participants	_
40-4	6327-6331	will	_
40-5	6332-6334	be	_
40-6	6335-6336	1	_
40-7	6337-6338	)	_
40-8	6339-6343	aged	_
40-9	6344-6351	between	_
40-10	6352-6354	18	_
40-11	6355-6358	and	_
40-12	6359-6361	65	_
40-13	6362-6367	years	_
40-14	6368-6369	,	_
40-15	6370-6371	2	_
40-16	6372-6373	)	_
40-17	6374-6378	have	_
40-18	6379-6381	to	_
40-19	6382-6389	provide	_
40-20	6390-6398	informed	_
40-21	6399-6406	consent	_
40-22	6407-6408	,	_
40-23	6409-6410	3	_
40-24	6411-6412	)	_
40-25	6413-6415	be	_
40-26	6416-6428	right-handed	_
40-27	6429-6430	,	_
40-28	6431-6432	4	_
40-29	6433-6434	)	_
40-30	6435-6439	show	_
40-31	6440-6442	an	_
40-32	6443-6454	appropriate	_
40-33	6455-6468	comprehension	_
40-34	6469-6471	of	_
40-35	6472-6475	the	_
40-36	6476-6482	German	_
40-37	6483-6491	language	_
40-38	6492-6495	and	_
40-39	6496-6497	5	_
40-40	6498-6499	)	_
40-41	6500-6504	must	_
40-42	6505-6507	be	_
40-43	6508-6512	able	_
40-44	6513-6515	to	_
40-45	6516-6526	accurately	_
40-46	6527-6532	watch	_
40-47	6533-6539	visual	_
40-48	6540-6547	stimuli	_
40-49	6548-6550	in	_
40-50	6551-6554	the	_
40-51	6555-6562	scanner	_
40-52	6563-6574	environment	_
40-53	6575-6576	.	_

Text=Alcohol use disorder and depression will be diagnosed according to DSM-5 criteria and patients must be abstinent for at least 5 days before scanning.
41-1	6577-6584	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
41-2	6585-6588	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
41-3	6589-6597	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
41-4	6598-6601	and	_
41-5	6602-6612	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
41-6	6613-6617	will	_
41-7	6618-6620	be	_
41-8	6621-6630	diagnosed	_
41-9	6631-6640	according	_
41-10	6641-6643	to	_
41-11	6644-6649	DSM-5	_
41-12	6650-6658	criteria	_
41-13	6659-6662	and	_
41-14	6663-6671	patients	_
41-15	6672-6676	must	_
41-16	6677-6679	be	_
41-17	6680-6689	abstinent	_
41-18	6690-6693	for	_
41-19	6694-6696	at	_
41-20	6697-6702	least	_
41-21	6703-6704	5	_
41-22	6705-6709	days	_
41-23	6710-6716	before	_
41-24	6717-6725	scanning	_
41-25	6726-6727	.	_

Text=Exclusion criteria for all participants include 1) psychiatric Axis I disorders as measured by the SCID I interview within the past 12-months (except for patients alcohol and nicotine abuse and depressive symptoms), 2) neurological disorders, 3) MRI specific contraindications such as having a pace maker or implanted metal, 4) positive drug screening (opioids, cannabinoids, benzodiazepines, barbiturates, cocaine, amphetamines), 5) any current psychoactive medication except anti-depressants, 6) pregnancy and 7) suicidal tendencies.
42-1	6728-6737	Exclusion	_
42-2	6738-6746	criteria	_
42-3	6747-6750	for	_
42-4	6751-6754	all	_
42-5	6755-6767	participants	_
42-6	6768-6775	include	_
42-7	6776-6777	1	_
42-8	6778-6779	)	_
42-9	6780-6791	psychiatric	_
42-10	6792-6796	Axis	_
42-11	6797-6798	I	_
42-12	6799-6808	disorders	_
42-13	6809-6811	as	_
42-14	6812-6820	measured	_
42-15	6821-6823	by	_
42-16	6824-6827	the	_
42-17	6828-6832	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
42-18	6833-6834	I	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
42-19	6835-6844	interview	_
42-20	6845-6851	within	_
42-21	6852-6855	the	_
42-22	6856-6860	past	_
42-23	6861-6870	12-months	_
42-24	6871-6872	(	_
42-25	6873-6879	except	_
42-26	6880-6883	for	_
42-27	6884-6892	patients	_
42-28	6893-6900	alcohol	_
42-29	6901-6904	and	_
42-30	6905-6913	nicotine	_
42-31	6914-6919	abuse	_
42-32	6920-6923	and	_
42-33	6924-6934	depressive	_
42-34	6935-6943	symptoms	_
42-35	6944-6945	)	_
42-36	6946-6947	,	_
42-37	6948-6949	2	_
42-38	6950-6951	)	_
42-39	6952-6964	neurological	_
42-40	6965-6974	disorders	_
42-41	6975-6976	,	_
42-42	6977-6978	3	_
42-43	6979-6980	)	_
42-44	6981-6984	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
42-45	6985-6993	specific	_
42-46	6994-7011	contraindications	_
42-47	7012-7016	such	_
42-48	7017-7019	as	_
42-49	7020-7026	having	_
42-50	7027-7028	a	_
42-51	7029-7033	pace	_
42-52	7034-7039	maker	_
42-53	7040-7042	or	_
42-54	7043-7052	implanted	_
42-55	7053-7058	metal	_
42-56	7059-7060	,	_
42-57	7061-7062	4	_
42-58	7063-7064	)	_
42-59	7065-7073	positive	_
42-60	7074-7078	drug	_
42-61	7079-7088	screening	_
42-62	7089-7090	(	_
42-63	7091-7098	opioids	_
42-64	7099-7100	,	_
42-65	7101-7113	cannabinoids	_
42-66	7114-7115	,	_
42-67	7116-7131	benzodiazepines	_
42-68	7132-7133	,	_
42-69	7134-7146	barbiturates	_
42-70	7147-7148	,	_
42-71	7149-7156	cocaine	_
42-72	7157-7158	,	_
42-73	7159-7171	amphetamines	_
42-74	7172-7173	)	_
42-75	7174-7175	,	_
42-76	7176-7177	5	_
42-77	7178-7179	)	_
42-78	7180-7183	any	_
42-79	7184-7191	current	_
42-80	7192-7204	psychoactive	_
42-81	7205-7215	medication	_
42-82	7216-7222	except	_
42-83	7223-7239	anti-depressants	_
42-84	7240-7241	,	_
42-85	7242-7243	6	_
42-86	7244-7245	)	_
42-87	7246-7255	pregnancy	_
42-88	7256-7259	and	_
42-89	7260-7261	7	_
42-90	7262-7263	)	_
42-91	7264-7272	suicidal	_
42-92	7273-7283	tendencies	_
42-93	7284-7285	.	_

Text=During the participation in the group therapies, comorbid participants should not enroll in any other CBT or individual psychotherapeutic treatment.
43-1	7286-7292	During	_
43-2	7293-7296	the	_
43-3	7297-7310	participation	_
43-4	7311-7313	in	_
43-5	7314-7317	the	_
43-6	7318-7323	group	_
43-7	7324-7333	therapies	_
43-8	7334-7335	,	_
43-9	7336-7344	comorbid	_
43-10	7345-7357	participants	_
43-11	7358-7364	should	_
43-12	7365-7368	not	_
43-13	7369-7375	enroll	_
43-14	7376-7378	in	_
43-15	7379-7382	any	_
43-16	7383-7388	other	_
43-17	7389-7392	CBT	_
43-18	7393-7395	or	_
43-19	7396-7406	individual	_
43-20	7407-7424	psychotherapeutic	_
43-21	7425-7434	treatment	_
43-22	7435-7436	.	_

Text=Sample size Power calculations were conducted by means of the G * Power 3.1 software package.
44-1	7437-7443	Sample	_
44-2	7444-7448	size	_
44-3	7449-7454	Power	_
44-4	7455-7467	calculations	_
44-5	7468-7472	were	_
44-6	7473-7482	conducted	_
44-7	7483-7485	by	_
44-8	7486-7491	means	_
44-9	7492-7494	of	_
44-10	7495-7498	the	_
44-11	7499-7500	G	_
44-12	7501-7502	*	_
44-13	7503-7508	Power	_
44-14	7509-7512	3.1	_
44-15	7513-7521	software	_
44-16	7522-7529	package	_
44-17	7530-7531	.	_

Text=According to pilot studies, an effect size of at least d = 1 can be assumed for the different paradigms and comparisons.
45-1	7532-7541	According	_
45-2	7542-7544	to	_
45-3	7545-7550	pilot	_
45-4	7551-7558	studies	_
45-5	7559-7560	,	_
45-6	7561-7563	an	_
45-7	7564-7570	effect	_
45-8	7571-7575	size	_
45-9	7576-7578	of	_
45-10	7579-7581	at	_
45-11	7582-7587	least	_
45-12	7588-7589	d	_
45-13	7590-7591	=	_
45-14	7592-7593	1	_
45-15	7594-7597	can	_
45-16	7598-7600	be	_
45-17	7601-7608	assumed	_
45-18	7609-7612	for	_
45-19	7613-7616	the	_
45-20	7617-7626	different	_
45-21	7627-7636	paradigms	_
45-22	7637-7640	and	_
45-23	7641-7652	comparisons	_
45-24	7653-7654	.	_

Text=For region of interest analysis with regions of 200 voxels, a sample of 30 per group should be sufficient to reach a power of 80% to detect differences at p <.05 (Bonferroni corrected for multiple tests).
46-1	7655-7658	For	_
46-2	7659-7665	region	_
46-3	7666-7668	of	_
46-4	7669-7677	interest	_
46-5	7678-7686	analysis	_
46-6	7687-7691	with	_
46-7	7692-7699	regions	_
46-8	7700-7702	of	_
46-9	7703-7706	200	_
46-10	7707-7713	voxels	_
46-11	7714-7715	,	_
46-12	7716-7717	a	_
46-13	7718-7724	sample	_
46-14	7725-7727	of	_
46-15	7728-7730	30	_
46-16	7731-7734	per	_
46-17	7735-7740	group	_
46-18	7741-7747	should	_
46-19	7748-7750	be	_
46-20	7751-7761	sufficient	_
46-21	7762-7764	to	_
46-22	7765-7770	reach	_
46-23	7771-7772	a	_
46-24	7773-7778	power	_
46-25	7779-7781	of	_
46-26	7782-7784	80	_
46-27	7785-7786	%	_
46-28	7787-7789	to	_
46-29	7790-7796	detect	_
46-30	7797-7808	differences	_
46-31	7809-7811	at	_
46-32	7812-7813	p	_
46-33	7814-7815	<	_
46-34	7816-7819	.05	_
46-35	7820-7821	(	_
46-36	7822-7832	Bonferroni	_
46-37	7833-7842	corrected	_
46-38	7843-7846	for	_
46-39	7847-7855	multiple	_
46-40	7856-7861	tests	_
46-41	7862-7863	)	_
46-42	7864-7865	.	_

Text=For the intervention study the same comorbid alcohol dependent and depressed participants will be randomly assigned to one of two group therapy interventions and asked to participate in a second fMRI session and follow up measurement.
47-1	7866-7869	For	_
47-2	7870-7873	the	_
47-3	7874-7886	intervention	_
47-4	7887-7892	study	_
47-5	7893-7896	the	_
47-6	7897-7901	same	_
47-7	7902-7910	comorbid	_
47-8	7911-7918	alcohol	_
47-9	7919-7928	dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
47-10	7929-7932	and	_
47-11	7933-7942	depressed	_
47-12	7943-7955	participants	_
47-13	7956-7960	will	_
47-14	7961-7963	be	_
47-15	7964-7972	randomly	_
47-16	7973-7981	assigned	_
47-17	7982-7984	to	_
47-18	7985-7988	one	_
47-19	7989-7991	of	_
47-20	7992-7995	two	_
47-21	7996-8001	group	_
47-22	8002-8009	therapy	_
47-23	8010-8023	interventions	_
47-24	8024-8027	and	_
47-25	8028-8033	asked	_
47-26	8034-8036	to	_
47-27	8037-8048	participate	_
47-28	8049-8051	in	_
47-29	8052-8053	a	_
47-30	8054-8060	second	_
47-31	8061-8065	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
47-32	8066-8073	session	_
47-33	8074-8077	and	_
47-34	8078-8084	follow	_
47-35	8085-8087	up	_
47-36	8088-8099	measurement	_
47-37	8100-8101	.	_

Text=When assuming a small to medium effect size (f = .2) for the group x time interaction and a correlation among repeated measures of.7 (as typical for fMRI data), we achieve a power of 80% to detect differences at p <.05 (Boferroni corrected for a k = 200, region of interest) on the neural level even when we have to face a drop-out rate of 10%.
48-1	8102-8106	When	_
48-2	8107-8115	assuming	_
48-3	8116-8117	a	_
48-4	8118-8123	small	_
48-5	8124-8126	to	_
48-6	8127-8133	medium	_
48-7	8134-8140	effect	_
48-8	8141-8145	size	_
48-9	8146-8147	(	_
48-10	8148-8149	f	_
48-11	8150-8151	=	_
48-12	8152-8154	.2	_
48-13	8155-8156	)	_
48-14	8157-8160	for	_
48-15	8161-8164	the	_
48-16	8165-8170	group	_
48-17	8171-8172	x	_
48-18	8173-8177	time	_
48-19	8178-8189	interaction	_
48-20	8190-8193	and	_
48-21	8194-8195	a	_
48-22	8196-8207	correlation	_
48-23	8208-8213	among	_
48-24	8214-8222	repeated	_
48-25	8223-8231	measures	_
48-26	8232-8236	of.7	_
48-27	8237-8238	(	_
48-28	8239-8241	as	_
48-29	8242-8249	typical	_
48-30	8250-8253	for	_
48-31	8254-8258	fMRI	_
48-32	8259-8263	data	_
48-33	8264-8265	)	_
48-34	8266-8267	,	_
48-35	8268-8270	we	_
48-36	8271-8278	achieve	_
48-37	8279-8280	a	_
48-38	8281-8286	power	_
48-39	8287-8289	of	_
48-40	8290-8292	80	_
48-41	8293-8294	%	_
48-42	8295-8297	to	_
48-43	8298-8304	detect	_
48-44	8305-8316	differences	_
48-45	8317-8319	at	_
48-46	8320-8321	p	_
48-47	8322-8323	<	_
48-48	8324-8327	.05	_
48-49	8328-8329	(	_
48-50	8330-8339	Boferroni	_
48-51	8340-8349	corrected	_
48-52	8350-8353	for	_
48-53	8354-8355	a	_
48-54	8356-8357	k	_
48-55	8358-8359	=	_
48-56	8360-8363	200	_
48-57	8364-8365	,	_
48-58	8366-8372	region	_
48-59	8373-8375	of	_
48-60	8376-8384	interest	_
48-61	8385-8386	)	_
48-62	8387-8389	on	_
48-63	8390-8393	the	_
48-64	8394-8400	neural	_
48-65	8401-8406	level	_
48-66	8407-8411	even	_
48-67	8412-8416	when	_
48-68	8417-8419	we	_
48-69	8420-8424	have	_
48-70	8425-8427	to	_
48-71	8428-8432	face	_
48-72	8433-8434	a	_
48-73	8435-8443	drop-out	_
48-74	8444-8448	rate	_
48-75	8449-8451	of	_
48-76	8452-8454	10	_
48-77	8455-8456	%	_
48-78	8457-8458	.	_

Text=While we expect an attrition rate of 20%, recruitment will be continued until the desired sample sizes are reached and drop-outs will be replaced by new participants.
49-1	8459-8464	While	_
49-2	8465-8467	we	_
49-3	8468-8474	expect	_
49-4	8475-8477	an	_
49-5	8478-8487	attrition	_
49-6	8488-8492	rate	_
49-7	8493-8495	of	_
49-8	8496-8498	20	_
49-9	8499-8500	%	_
49-10	8501-8502	,	_
49-11	8503-8514	recruitment	_
49-12	8515-8519	will	_
49-13	8520-8522	be	_
49-14	8523-8532	continued	_
49-15	8533-8538	until	_
49-16	8539-8542	the	_
49-17	8543-8550	desired	_
49-18	8551-8557	sample	_
49-19	8558-8563	sizes	_
49-20	8564-8567	are	_
49-21	8568-8575	reached	_
49-22	8576-8579	and	_
49-23	8580-8589	drop-outs	_
49-24	8590-8594	will	_
49-25	8595-8597	be	_
49-26	8598-8606	replaced	_
49-27	8607-8609	by	_
49-28	8610-8613	new	_
49-29	8614-8626	participants	_
49-30	8627-8628	.	_

Text=Sample recruitment Participants of the study are recruited by means of several sources in the community around Mannheim, Germany.
50-1	8629-8635	Sample	_
50-2	8636-8647	recruitment	_
50-3	8648-8660	Participants	_
50-4	8661-8663	of	_
50-5	8664-8667	the	_
50-6	8668-8673	study	_
50-7	8674-8677	are	_
50-8	8678-8687	recruited	_
50-9	8688-8690	by	_
50-10	8691-8696	means	_
50-11	8697-8699	of	_
50-12	8700-8707	several	_
50-13	8708-8715	sources	_
50-14	8716-8718	in	_
50-15	8719-8722	the	_
50-16	8723-8732	community	_
50-17	8733-8739	around	_
50-18	8740-8748	Mannheim	_
50-19	8749-8750	,	_
50-20	8751-8758	Germany	_
50-21	8759-8760	.	_

Text=These include advertisement in local newspapers, announcements on our institutes ’ homepage, flyers in local businesses and university campuses; and contact with potential referral sources, for example general practitioners, private psychologists and psychiatrists, as well as local psychiatric inpatient and outpatient units.
51-1	8761-8766	These	_
51-2	8767-8774	include	_
51-3	8775-8788	advertisement	_
51-4	8789-8791	in	_
51-5	8792-8797	local	_
51-6	8798-8808	newspapers	_
51-7	8809-8810	,	_
51-8	8811-8824	announcements	_
51-9	8825-8827	on	_
51-10	8828-8831	our	_
51-11	8832-8842	institutes	_
51-12	8843-8844	’	_
51-13	8845-8853	homepage	_
51-14	8854-8855	,	_
51-15	8856-8862	flyers	_
51-16	8863-8865	in	_
51-17	8866-8871	local	_
51-18	8872-8882	businesses	_
51-19	8883-8886	and	_
51-20	8887-8897	university	_
51-21	8898-8906	campuses	_
51-22	8907-8908	;	_
51-23	8909-8912	and	_
51-24	8913-8920	contact	_
51-25	8921-8925	with	_
51-26	8926-8935	potential	_
51-27	8936-8944	referral	_
51-28	8945-8952	sources	_
51-29	8953-8954	,	_
51-30	8955-8958	for	_
51-31	8959-8966	example	_
51-32	8967-8974	general	_
51-33	8975-8988	practitioners	_
51-34	8989-8990	,	_
51-35	8991-8998	private	_
51-36	8999-9012	psychologists	_
51-37	9013-9016	and	_
51-38	9017-9030	psychiatrists	_
51-39	9031-9032	,	_
51-40	9033-9035	as	_
51-41	9036-9040	well	_
51-42	9041-9043	as	_
51-43	9044-9049	local	_
51-44	9050-9061	psychiatric	_
51-45	9062-9071	inpatient	_
51-46	9072-9075	and	_
51-47	9076-9086	outpatient	_
51-48	9087-9092	units	_
51-49	9093-9094	.	_

Text=Prospective participants express their interest to the research team through email or phone call.
52-1	9095-9106	Prospective	_
52-2	9107-9119	participants	_
52-3	9120-9127	express	_
52-4	9128-9133	their	_
52-5	9134-9142	interest	_
52-6	9143-9145	to	_
52-7	9146-9149	the	_
52-8	9150-9158	research	_
52-9	9159-9163	team	_
52-10	9164-9171	through	_
52-11	9172-9177	email	_
52-12	9178-9180	or	_
52-13	9181-9186	phone	_
52-14	9187-9191	call	_
52-15	9192-9193	.	_

Text=After carefully informing the participants about the aim, content, duration and potential risks and benefits of the study, trained research assistants assess initial eligibility using a specifically developed telephone screening.
53-1	9194-9199	After	_
53-2	9200-9209	carefully	_
53-3	9210-9219	informing	_
53-4	9220-9223	the	_
53-5	9224-9236	participants	_
53-6	9237-9242	about	_
53-7	9243-9246	the	_
53-8	9247-9250	aim	_
53-9	9251-9252	,	_
53-10	9253-9260	content	_
53-11	9261-9262	,	_
53-12	9263-9271	duration	_
53-13	9272-9275	and	_
53-14	9276-9285	potential	_
53-15	9286-9291	risks	_
53-16	9292-9295	and	_
53-17	9296-9304	benefits	_
53-18	9305-9307	of	_
53-19	9308-9311	the	_
53-20	9312-9317	study	_
53-21	9318-9319	,	_
53-22	9320-9327	trained	_
53-23	9328-9336	research	_
53-24	9337-9347	assistants	_
53-25	9348-9354	assess	_
53-26	9355-9362	initial	_
53-27	9363-9374	eligibility	_
53-28	9375-9380	using	_
53-29	9381-9382	a	_
53-30	9383-9395	specifically	_
53-31	9396-9405	developed	_
53-32	9406-9415	telephone	_
53-33	9416-9425	screening	_
53-34	9426-9427	.	_

Text=In case the participants are currently in one of the local inpatient or outpatient facilities of the institute, participants will be personally approached and screened.
54-1	9428-9430	In	_
54-2	9431-9435	case	_
54-3	9436-9439	the	_
54-4	9440-9452	participants	_
54-5	9453-9456	are	_
54-6	9457-9466	currently	_
54-7	9467-9469	in	_
54-8	9470-9473	one	_
54-9	9474-9476	of	_
54-10	9477-9480	the	_
54-11	9481-9486	local	_
54-12	9487-9496	inpatient	_
54-13	9497-9499	or	_
54-14	9500-9510	outpatient	_
54-15	9511-9521	facilities	_
54-16	9522-9524	of	_
54-17	9525-9528	the	_
54-18	9529-9538	institute	_
54-19	9539-9540	,	_
54-20	9541-9553	participants	_
54-21	9554-9558	will	_
54-22	9559-9561	be	_
54-23	9562-9572	personally	_
54-24	9573-9583	approached	_
54-25	9584-9587	and	_
54-26	9588-9596	screened	_
54-27	9597-9598	.	_

Text=If the individual meets the inclusion criteria, they receive a letter including a detailed study description, the informed consent, time and date of their study appointment and an online link with questionnaires.
55-1	9599-9601	If	_
55-2	9602-9605	the	_
55-3	9606-9616	individual	_
55-4	9617-9622	meets	_
55-5	9623-9626	the	_
55-6	9627-9636	inclusion	_
55-7	9637-9645	criteria	_
55-8	9646-9647	,	_
55-9	9648-9652	they	_
55-10	9653-9660	receive	_
55-11	9661-9662	a	_
55-12	9663-9669	letter	_
55-13	9670-9679	including	_
55-14	9680-9681	a	_
55-15	9682-9690	detailed	_
55-16	9691-9696	study	_
55-17	9697-9708	description	_
55-18	9709-9710	,	_
55-19	9711-9714	the	_
55-20	9715-9723	informed	_
55-21	9724-9731	consent	_
55-22	9732-9733	,	_
55-23	9734-9738	time	_
55-24	9739-9742	and	_
55-25	9743-9747	date	_
55-26	9748-9750	of	_
55-27	9751-9756	their	_
55-28	9757-9762	study	_
55-29	9763-9774	appointment	_
55-30	9775-9778	and	_
55-31	9779-9781	an	_
55-32	9782-9788	online	_
55-33	9789-9793	link	_
55-34	9794-9798	with	_
55-35	9799-9813	questionnaires	_
55-36	9814-9815	.	_

Text=Study procedure Before participants will be finally included in the study, any open questions, risks and benefits will be discussed with a trained psychologist at the T1 assessment.
56-1	9816-9821	Study	_
56-2	9822-9831	procedure	_
56-3	9832-9838	Before	_
56-4	9839-9851	participants	_
56-5	9852-9856	will	_
56-6	9857-9859	be	_
56-7	9860-9867	finally	_
56-8	9868-9876	included	_
56-9	9877-9879	in	_
56-10	9880-9883	the	_
56-11	9884-9889	study	_
56-12	9890-9891	,	_
56-13	9892-9895	any	_
56-14	9896-9900	open	_
56-15	9901-9910	questions	_
56-16	9911-9912	,	_
56-17	9913-9918	risks	_
56-18	9919-9922	and	_
56-19	9923-9931	benefits	_
56-20	9932-9936	will	_
56-21	9937-9939	be	_
56-22	9940-9949	discussed	_
56-23	9950-9954	with	_
56-24	9955-9956	a	_
56-25	9957-9964	trained	_
56-26	9965-9977	psychologist	_
56-27	9978-9980	at	_
56-28	9981-9984	the	_
56-29	9985-9987	T1	_
56-30	9988-9998	assessment	_
56-31	9999-10000	.	_

Text=On agreement of the participant, the informed consent form will be signed and a copy handed to the participant.
57-1	10001-10003	On	_
57-2	10004-10013	agreement	_
57-3	10014-10016	of	_
57-4	10017-10020	the	_
57-5	10021-10032	participant	_
57-6	10033-10034	,	_
57-7	10035-10038	the	_
57-8	10039-10047	informed	_
57-9	10048-10055	consent	_
57-10	10056-10060	form	_
57-11	10061-10065	will	_
57-12	10066-10068	be	_
57-13	10069-10075	signed	_
57-14	10076-10079	and	_
57-15	10080-10081	a	_
57-16	10082-10086	copy	_
57-17	10087-10093	handed	_
57-18	10094-10096	to	_
57-19	10097-10100	the	_
57-20	10101-10112	participant	_
57-21	10113-10114	.	_

Text=Afterwards, participants will undergo a psychological interview assessing previously received therapy, current medication and for patients symptoms of depression or alcohol use disorder according to DSM-5.
58-1	10115-10125	Afterwards	_
58-2	10126-10127	,	_
58-3	10128-10140	participants	_
58-4	10141-10145	will	_
58-5	10146-10153	undergo	_
58-6	10154-10155	a	_
58-7	10156-10169	psychological	_
58-8	10170-10179	interview	_
58-9	10180-10189	assessing	_
58-10	10190-10200	previously	_
58-11	10201-10209	received	_
58-12	10210-10217	therapy	_
58-13	10218-10219	,	_
58-14	10220-10227	current	_
58-15	10228-10238	medication	_
58-16	10239-10242	and	_
58-17	10243-10246	for	_
58-18	10247-10255	patients	_
58-19	10256-10264	symptoms	_
58-20	10265-10267	of	_
58-21	10268-10278	depression	_
58-22	10279-10281	or	_
58-23	10282-10289	alcohol	_
58-24	10290-10293	use	_
58-25	10294-10302	disorder	_
58-26	10303-10312	according	_
58-27	10313-10315	to	_
58-28	10316-10321	DSM-5	_
58-29	10322-10323	.	_

Text=Before the fMRI measurement starts, all paradigms are explained to the participant.
59-1	10324-10330	Before	_
59-2	10331-10334	the	_
59-3	10335-10339	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
59-4	10340-10351	measurement	_
59-5	10352-10358	starts	_
59-6	10359-10360	,	_
59-7	10361-10364	all	_
59-8	10365-10374	paradigms	_
59-9	10375-10378	are	_
59-10	10379-10388	explained	_
59-11	10389-10391	to	_
59-12	10392-10395	the	_
59-13	10396-10407	participant	_
59-14	10408-10409	.	_

Text=Also before and after the fMRI session, participants are asked to fill out questionnaires regarding their current mood and craving.
60-1	10410-10414	Also	_
60-2	10415-10421	before	_
60-3	10422-10425	and	_
60-4	10426-10431	after	_
60-5	10432-10435	the	_
60-6	10436-10440	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
60-7	10441-10448	session	_
60-8	10449-10450	,	_
60-9	10451-10463	participants	_
60-10	10464-10467	are	_
60-11	10468-10473	asked	_
60-12	10474-10476	to	_
60-13	10477-10481	fill	_
60-14	10482-10485	out	_
60-15	10486-10500	questionnaires	_
60-16	10501-10510	regarding	_
60-17	10511-10516	their	_
60-18	10517-10524	current	_
60-19	10525-10529	mood	_
60-20	10530-10533	and	_
60-21	10534-10541	craving	_
60-22	10542-10543	.	_

Text=Only comorbid alcohol dependent and depressed patients will be randomized to either receive BAT or MBT group training for 6 weeks.
61-1	10544-10548	Only	_
61-2	10549-10557	comorbid	_
61-3	10558-10565	alcohol	_
61-4	10566-10575	dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
61-5	10576-10579	and	_
61-6	10580-10589	depressed	_
61-7	10590-10598	patients	_
61-8	10599-10603	will	_
61-9	10604-10606	be	_
61-10	10607-10617	randomized	_
61-11	10618-10620	to	_
61-12	10621-10627	either	_
61-13	10628-10635	receive	_
61-14	10636-10639	BAT	_
61-15	10640-10642	or	_
61-16	10643-10646	MBT	_
61-17	10647-10652	group	_
61-18	10653-10661	training	_
61-19	10662-10665	for	_
61-20	10666-10667	6	_
61-21	10668-10673	weeks	_
61-22	10674-10675	.	_

Text=For comorbid patients, the fMRI procedure followed at T1 will be repeated at T2.
62-1	10676-10679	For	_
62-2	10680-10688	comorbid	_
62-3	10689-10697	patients	_
62-4	10698-10699	,	_
62-5	10700-10703	the	_
62-6	10704-10708	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
62-7	10709-10718	procedure	_
62-8	10719-10727	followed	_
62-9	10728-10730	at	_
62-10	10731-10733	T1	_
62-11	10734-10738	will	_
62-12	10739-10741	be	_
62-13	10742-10750	repeated	_
62-14	10751-10753	at	_
62-15	10754-10756	T2	_
62-16	10757-10758	.	_

Text=Afterwards, comorbid patients will be contacted after three months for a catamnestic exploration.
63-1	10759-10769	Afterwards	_
63-2	10770-10771	,	_
63-3	10772-10780	comorbid	_
63-4	10781-10789	patients	_
63-5	10790-10794	will	_
63-6	10795-10797	be	_
63-7	10798-10807	contacted	_
63-8	10808-10813	after	_
63-9	10814-10819	three	_
63-10	10820-10826	months	_
63-11	10827-10830	for	_
63-12	10831-10832	a	_
63-13	10833-10844	catamnestic	_
63-14	10845-10856	exploration	_
63-15	10857-10858	.	_

Text=All participants will be compensated for their time with 15€ per scanning session plus the money won in the reward paradigm.
64-1	10859-10862	All	_
64-2	10863-10875	participants	_
64-3	10876-10880	will	_
64-4	10881-10883	be	_
64-5	10884-10895	compensated	_
64-6	10896-10899	for	_
64-7	10900-10905	their	_
64-8	10906-10910	time	_
64-9	10911-10915	with	_
64-10	10916-10919	15€	_
64-11	10920-10923	per	_
64-12	10924-10932	scanning	_
64-13	10933-10940	session	_
64-14	10941-10945	plus	_
64-15	10946-10949	the	_
64-16	10950-10955	money	_
64-17	10956-10959	won	_
64-18	10960-10962	in	_
64-19	10963-10966	the	_
64-20	10967-10973	reward	_
64-21	10974-10982	paradigm	_
64-22	10983-10984	.	_

Text=To promote participant retention and complete follow-up we will contact the comorbid patients by phone during the follow-up period.
65-1	10985-10987	To	_
65-2	10988-10995	promote	_
65-3	10996-11007	participant	_
65-4	11008-11017	retention	_
65-5	11018-11021	and	_
65-6	11022-11030	complete	_
65-7	11031-11040	follow-up	_
65-8	11041-11043	we	_
65-9	11044-11048	will	_
65-10	11049-11056	contact	_
65-11	11057-11060	the	_
65-12	11061-11069	comorbid	_
65-13	11070-11078	patients	_
65-14	11079-11081	by	_
65-15	11082-11087	phone	_
65-16	11088-11094	during	_
65-17	11095-11098	the	_
65-18	11099-11108	follow-up	_
65-19	11109-11115	period	_
65-20	11116-11117	.	_

Text=Randomization After completion of baseline assessment, comorbid patients will be randomly assigned to one of the two group interventions.
66-1	11118-11131	Randomization	_
66-2	11132-11137	After	_
66-3	11138-11148	completion	_
66-4	11149-11151	of	_
66-5	11152-11160	baseline	_
66-6	11161-11171	assessment	_
66-7	11172-11173	,	_
66-8	11174-11182	comorbid	_
66-9	11183-11191	patients	_
66-10	11192-11196	will	_
66-11	11197-11199	be	_
66-12	11200-11208	randomly	_
66-13	11209-11217	assigned	_
66-14	11218-11220	to	_
66-15	11221-11224	one	_
66-16	11225-11227	of	_
66-17	11228-11231	the	_
66-18	11232-11235	two	_
66-19	11236-11241	group	_
66-20	11242-11255	interventions	_
66-21	11256-11257	.	_

Text=To reduce the time between the initial study recruitment and the start of the group therapy, the randomization order will be determined with a block randomization with 6 participants per block for each treatment arm.
67-1	11258-11260	To	_
67-2	11261-11267	reduce	_
67-3	11268-11271	the	_
67-4	11272-11276	time	_
67-5	11277-11284	between	_
67-6	11285-11288	the	_
67-7	11289-11296	initial	_
67-8	11297-11302	study	_
67-9	11303-11314	recruitment	_
67-10	11315-11318	and	_
67-11	11319-11322	the	_
67-12	11323-11328	start	_
67-13	11329-11331	of	_
67-14	11332-11335	the	_
67-15	11336-11341	group	_
67-16	11342-11349	therapy	_
67-17	11350-11351	,	_
67-18	11352-11355	the	_
67-19	11356-11369	randomization	_
67-20	11370-11375	order	_
67-21	11376-11380	will	_
67-22	11381-11383	be	_
67-23	11384-11394	determined	_
67-24	11395-11399	with	_
67-25	11400-11401	a	_
67-26	11402-11407	block	_
67-27	11408-11421	randomization	_
67-28	11422-11426	with	_
67-29	11427-11428	6	_
67-30	11429-11441	participants	_
67-31	11442-11445	per	_
67-32	11446-11451	block	_
67-33	11452-11455	for	_
67-34	11456-11460	each	_
67-35	11461-11470	treatment	_
67-36	11471-11474	arm	_
67-37	11475-11476	.	_

Text=Randomization will be performed by a researcher who is not involved in the recruitment, using a computerized randomization tool implemented in MATLAB (The MathWorks Inc., Natick, Massachusetts, United States).
68-1	11477-11490	Randomization	_
68-2	11491-11495	will	_
68-3	11496-11498	be	_
68-4	11499-11508	performed	_
68-5	11509-11511	by	_
68-6	11512-11513	a	_
68-7	11514-11524	researcher	_
68-8	11525-11528	who	_
68-9	11529-11531	is	_
68-10	11532-11535	not	_
68-11	11536-11544	involved	_
68-12	11545-11547	in	_
68-13	11548-11551	the	_
68-14	11552-11563	recruitment	_
68-15	11564-11565	,	_
68-16	11566-11571	using	_
68-17	11572-11573	a	_
68-18	11574-11586	computerized	_
68-19	11587-11600	randomization	_
68-20	11601-11605	tool	_
68-21	11606-11617	implemented	_
68-22	11618-11620	in	_
68-23	11621-11627	MATLAB	_
68-24	11628-11629	(	_
68-25	11630-11633	The	_
68-26	11634-11643	MathWorks	_
68-27	11644-11648	Inc.	_
68-28	11649-11650	,	_
68-29	11651-11657	Natick	_
68-30	11658-11659	,	_
68-31	11660-11673	Massachusetts	_
68-32	11674-11675	,	_
68-33	11676-11682	United	_
68-34	11683-11689	States	_
68-35	11690-11691	)	_
68-36	11692-11693	.	_

Text=Participants will be recruited and enrolled by trained research staff; the allocation sequence will be concealed from them.
69-1	11694-11706	Participants	_
69-2	11707-11711	will	_
69-3	11712-11714	be	_
69-4	11715-11724	recruited	_
69-5	11725-11728	and	_
69-6	11729-11737	enrolled	_
69-7	11738-11740	by	_
69-8	11741-11748	trained	_
69-9	11749-11757	research	_
69-10	11758-11763	staff	_
69-11	11764-11765	;	_
69-12	11766-11769	the	_
69-13	11770-11780	allocation	_
69-14	11781-11789	sequence	_
69-15	11790-11794	will	_
69-16	11795-11797	be	_
69-17	11798-11807	concealed	_
69-18	11808-11812	from	_
69-19	11813-11817	them	_
69-20	11818-11819	.	_

Text=Since the study offers psychotherapeutic interventions, patients are not blinded to their intervention arms.
70-1	11820-11825	Since	_
70-2	11826-11829	the	_
70-3	11830-11835	study	_
70-4	11836-11842	offers	_
70-5	11843-11860	psychotherapeutic	_
70-6	11861-11874	interventions	_
70-7	11875-11876	,	_
70-8	11877-11885	patients	_
70-9	11886-11889	are	_
70-10	11890-11893	not	_
70-11	11894-11901	blinded	_
70-12	11902-11904	to	_
70-13	11905-11910	their	_
70-14	11911-11923	intervention	_
70-15	11924-11928	arms	_
70-16	11929-11930	.	_

Text=Psychotherapeutic Interventions Comorbid patients will be randomly assigned to one of two group therapies consisting of 6 participants.
71-1	11931-11948	Psychotherapeutic	_
71-2	11949-11962	Interventions	_
71-3	11963-11971	Comorbid	_
71-4	11972-11980	patients	_
71-5	11981-11985	will	_
71-6	11986-11988	be	_
71-7	11989-11997	randomly	_
71-8	11998-12006	assigned	_
71-9	12007-12009	to	_
71-10	12010-12013	one	_
71-11	12014-12016	of	_
71-12	12017-12020	two	_
71-13	12021-12026	group	_
71-14	12027-12036	therapies	_
71-15	12037-12047	consisting	_
71-16	12048-12050	of	_
71-17	12051-12052	6	_
71-18	12053-12065	participants	_
71-19	12066-12067	.	_

Text=Both interventions consist of six sessions of 2 h therapy with 1 session per week offered by a psychotherapist.
72-1	12068-12072	Both	_
72-2	12073-12086	interventions	_
72-3	12087-12094	consist	_
72-4	12095-12097	of	_
72-5	12098-12101	six	_
72-6	12102-12110	sessions	_
72-7	12111-12113	of	_
72-8	12114-12115	2	_
72-9	12116-12117	h	_
72-10	12118-12125	therapy	_
72-11	12126-12130	with	_
72-12	12131-12132	1	_
72-13	12133-12140	session	_
72-14	12141-12144	per	_
72-15	12145-12149	week	_
72-16	12150-12157	offered	_
72-17	12158-12160	by	_
72-18	12161-12162	a	_
72-19	12163-12178	psychotherapist	_
72-20	12179-12180	.	_

Text=To increase adherence, ﻿each participant will receive an individual therapy session before the group therapy begins.
73-1	12181-12183	To	_
73-2	12184-12192	increase	_
73-3	12193-12202	adherence	_
73-4	12203-12204	,	_
73-5	12205-12210	﻿each	_
73-6	12211-12222	participant	_
73-7	12223-12227	will	_
73-8	12228-12235	receive	_
73-9	12236-12238	an	_
73-10	12239-12249	individual	_
73-11	12250-12257	therapy	_
73-12	12258-12265	session	_
73-13	12266-12272	before	_
73-14	12273-12276	the	_
73-15	12277-12282	group	_
73-16	12283-12290	therapy	_
73-17	12291-12297	begins	_
73-18	12298-12299	.	_

Text=The group therapy protocols in both arms are manualized and supervised by an experienced psychotherapist to ensure protocol adherence.
74-1	12300-12303	The	_
74-2	12304-12309	group	_
74-3	12310-12317	therapy	_
74-4	12318-12327	protocols	_
74-5	12328-12330	in	_
74-6	12331-12335	both	_
74-7	12336-12340	arms	_
74-8	12341-12344	are	_
74-9	12345-12355	manualized	_
74-10	12356-12359	and	_
74-11	12360-12370	supervised	_
74-12	12371-12373	by	_
74-13	12374-12376	an	_
74-14	12377-12388	experienced	_
74-15	12389-12404	psychotherapist	_
74-16	12405-12407	to	_
74-17	12408-12414	ensure	_
74-18	12415-12423	protocol	_
74-19	12424-12433	adherence	_
74-20	12434-12435	.	_

Text=Patients who missed more than one session or experienced a severe relapse during the intervention period will be excluded from the protocol.
75-1	12436-12444	Patients	_
75-2	12445-12448	who	_
75-3	12449-12455	missed	_
75-4	12456-12460	more	_
75-5	12461-12465	than	_
75-6	12466-12469	one	_
75-7	12470-12477	session	_
75-8	12478-12480	or	_
75-9	12481-12492	experienced	_
75-10	12493-12494	a	_
75-11	12495-12501	severe	_
75-12	12502-12509	relapse	_
75-13	12510-12516	during	_
75-14	12517-12520	the	_
75-15	12521-12533	intervention	_
75-16	12534-12540	period	_
75-17	12541-12545	will	_
75-18	12546-12548	be	_
75-19	12549-12557	excluded	_
75-20	12558-12562	from	_
75-21	12563-12566	the	_
75-22	12567-12575	protocol	_
75-23	12576-12577	.	_

Text=In the unexpected case of an adverse event or harm during the psychotherapeutic intervention (for example, severe aggravation like suicidality), the affected patient will also be excluded and additional in- or outpatient treatment will be offered by the psychotherapist.
76-1	12578-12580	In	_
76-2	12581-12584	the	_
76-3	12585-12595	unexpected	_
76-4	12596-12600	case	_
76-5	12601-12603	of	_
76-6	12604-12606	an	_
76-7	12607-12614	adverse	_
76-8	12615-12620	event	_
76-9	12621-12623	or	_
76-10	12624-12628	harm	_
76-11	12629-12635	during	_
76-12	12636-12639	the	_
76-13	12640-12657	psychotherapeutic	_
76-14	12658-12670	intervention	_
76-15	12671-12672	(	_
76-16	12673-12676	for	_
76-17	12677-12684	example	_
76-18	12685-12686	,	_
76-19	12687-12693	severe	_
76-20	12694-12705	aggravation	_
76-21	12706-12710	like	_
76-22	12711-12722	suicidality	_
76-23	12723-12724	)	_
76-24	12725-12726	,	_
76-25	12727-12730	the	_
76-26	12731-12739	affected	_
76-27	12740-12747	patient	_
76-28	12748-12752	will	_
76-29	12753-12757	also	_
76-30	12758-12760	be	_
76-31	12761-12769	excluded	_
76-32	12770-12773	and	_
76-33	12774-12784	additional	_
76-34	12785-12788	in-	_
76-35	12789-12791	or	_
76-36	12792-12802	outpatient	_
76-37	12803-12812	treatment	_
76-38	12813-12817	will	_
76-39	12818-12820	be	_
76-40	12821-12828	offered	_
76-41	12829-12831	by	_
76-42	12832-12835	the	_
76-43	12836-12851	psychotherapist	_
76-44	12852-12853	.	_

Text=Behavioral activation treatment Behavioral Activation Treatment (BAT) is a structured and validated psychotherapy intervention designed to increase engagement with functional, potentially rewarding behaviors.
77-1	12854-12864	Behavioral	_
77-2	12865-12875	activation	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
77-3	12876-12885	treatment	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
77-4	12886-12896	Behavioral	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
77-5	12897-12907	Activation	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
77-6	12908-12917	Treatment	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
77-7	12918-12919	(	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
77-8	12920-12923	BAT	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
77-9	12924-12925	)	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
77-10	12926-12928	is	_
77-11	12929-12930	a	_
77-12	12931-12941	structured	_
77-13	12942-12945	and	_
77-14	12946-12955	validated	_
77-15	12956-12969	psychotherapy	_
77-16	12970-12982	intervention	_
77-17	12983-12991	designed	_
77-18	12992-12994	to	_
77-19	12995-13003	increase	_
77-20	13004-13014	engagement	_
77-21	13015-13019	with	_
77-22	13020-13030	functional	_
77-23	13031-13032	,	_
77-24	13033-13044	potentially	_
77-25	13045-13054	rewarding	_
77-26	13055-13064	behaviors	_
77-27	13065-13066	.	_

Text=Treatment proceeds through a series of structured units that (a) provide psychoeducation about depression and alcohol dependence, as well as a rationale for the treatment approach, (b) assess and monitor baseline activity levels, (c) identify and support more functional behaviors and personally valued goals as an alternative strategy to cope with cravings and low mood, (d) monitor, support, and reward achieving behavioral goals, and (e) improve problem solving skills.
78-1	13067-13076	Treatment	_
78-2	13077-13085	proceeds	_
78-3	13086-13093	through	_
78-4	13094-13095	a	_
78-5	13096-13102	series	_
78-6	13103-13105	of	_
78-7	13106-13116	structured	_
78-8	13117-13122	units	_
78-9	13123-13127	that	_
78-10	13128-13129	(	_
78-11	13130-13131	a	_
78-12	13132-13133	)	_
78-13	13134-13141	provide	_
78-14	13142-13157	psychoeducation	_
78-15	13158-13163	about	_
78-16	13164-13174	depression	_
78-17	13175-13178	and	_
78-18	13179-13186	alcohol	_
78-19	13187-13197	dependence	_
78-20	13198-13199	,	_
78-21	13200-13202	as	_
78-22	13203-13207	well	_
78-23	13208-13210	as	_
78-24	13211-13212	a	_
78-25	13213-13222	rationale	_
78-26	13223-13226	for	_
78-27	13227-13230	the	_
78-28	13231-13240	treatment	_
78-29	13241-13249	approach	_
78-30	13250-13251	,	_
78-31	13252-13253	(	_
78-32	13254-13255	b	_
78-33	13256-13257	)	_
78-34	13258-13264	assess	_
78-35	13265-13268	and	_
78-36	13269-13276	monitor	_
78-37	13277-13285	baseline	_
78-38	13286-13294	activity	_
78-39	13295-13301	levels	_
78-40	13302-13303	,	_
78-41	13304-13305	(	_
78-42	13306-13307	c	_
78-43	13308-13309	)	_
78-44	13310-13318	identify	_
78-45	13319-13322	and	_
78-46	13323-13330	support	_
78-47	13331-13335	more	_
78-48	13336-13346	functional	_
78-49	13347-13356	behaviors	_
78-50	13357-13360	and	_
78-51	13361-13371	personally	_
78-52	13372-13378	valued	_
78-53	13379-13384	goals	_
78-54	13385-13387	as	_
78-55	13388-13390	an	_
78-56	13391-13402	alternative	_
78-57	13403-13411	strategy	_
78-58	13412-13414	to	_
78-59	13415-13419	cope	_
78-60	13420-13424	with	_
78-61	13425-13433	cravings	_
78-62	13434-13437	and	_
78-63	13438-13441	low	_
78-64	13442-13446	mood	_
78-65	13447-13448	,	_
78-66	13449-13450	(	_
78-67	13451-13452	d	_
78-68	13453-13454	)	_
78-69	13455-13462	monitor	_
78-70	13463-13464	,	_
78-71	13465-13472	support	_
78-72	13473-13474	,	_
78-73	13475-13478	and	_
78-74	13479-13485	reward	_
78-75	13486-13495	achieving	_
78-76	13496-13506	behavioral	_
78-77	13507-13512	goals	_
78-78	13513-13514	,	_
78-79	13515-13518	and	_
78-80	13519-13520	(	_
78-81	13521-13522	e	_
78-82	13523-13524	)	_
78-83	13525-13532	improve	_
78-84	13533-13540	problem	_
78-85	13541-13548	solving	_
78-86	13549-13555	skills	_
78-87	13556-13557	.	_

Text=Previous studies have demonstrated that BAT for depression effectively reduces depressive symptoms and is well tolerated in outpatient settings.
79-1	13558-13566	Previous	_
79-2	13567-13574	studies	_
79-3	13575-13579	have	_
79-4	13580-13592	demonstrated	_
79-5	13593-13597	that	_
79-6	13598-13601	BAT	_
79-7	13602-13605	for	_
79-8	13606-13616	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
79-9	13617-13628	effectively	_
79-10	13629-13636	reduces	_
79-11	13637-13647	depressive	_
79-12	13648-13656	symptoms	_
79-13	13657-13660	and	_
79-14	13661-13663	is	_
79-15	13664-13668	well	_
79-16	13669-13678	tolerated	_
79-17	13679-13681	in	_
79-18	13682-13692	outpatient	_
79-19	13693-13701	settings	_
79-20	13702-13703	.	_

Text=Mindfulness based therapy The mindfulness based intervention aims to increase awareness for and help patients to accept situational cues, negative thoughts, feelings, and behavioral impulses that have been associated with drinking.
80-1	13704-13715	Mindfulness	http://maven.renci.org/NeuroBridge/neurobridge#EcologicalStudy
80-2	13716-13721	based	http://maven.renci.org/NeuroBridge/neurobridge#EcologicalStudy
80-3	13722-13729	therapy	http://maven.renci.org/NeuroBridge/neurobridge#EcologicalStudy
80-4	13730-13733	The	_
80-5	13734-13745	mindfulness	_
80-6	13746-13751	based	http://maven.renci.org/NeuroBridge/neurobridge#EcologicalStudy
80-7	13752-13764	intervention	_
80-8	13765-13769	aims	_
80-9	13770-13772	to	_
80-10	13773-13781	increase	_
80-11	13782-13791	awareness	_
80-12	13792-13795	for	_
80-13	13796-13799	and	_
80-14	13800-13804	help	_
80-15	13805-13813	patients	_
80-16	13814-13816	to	_
80-17	13817-13823	accept	_
80-18	13824-13835	situational	_
80-19	13836-13840	cues	_
80-20	13841-13842	,	_
80-21	13843-13851	negative	_
80-22	13852-13860	thoughts	_
80-23	13861-13862	,	_
80-24	13863-13871	feelings	_
80-25	13872-13873	,	_
80-26	13874-13877	and	_
80-27	13878-13888	behavioral	_
80-28	13889-13897	impulses	_
80-29	13898-13902	that	_
80-30	13903-13907	have	_
80-31	13908-13912	been	_
80-32	13913-13923	associated	_
80-33	13924-13928	with	_
80-34	13929-13937	drinking	_
80-35	13938-13939	.	_

Text=Participants are guided through structured units that (a) provide psychoeducation about depression and alcohol dependence, as well as a rationale for the treatment approach, (b) increase patients ’ awareness of different experiences including low mood and cravings, (c) help clients to distance themselves from challenging experiences, e.g.
81-1	13940-13952	Participants	_
81-2	13953-13956	are	_
81-3	13957-13963	guided	_
81-4	13964-13971	through	_
81-5	13972-13982	structured	_
81-6	13983-13988	units	_
81-7	13989-13993	that	_
81-8	13994-13995	(	_
81-9	13996-13997	a	_
81-10	13998-13999	)	_
81-11	14000-14007	provide	_
81-12	14008-14023	psychoeducation	_
81-13	14024-14029	about	_
81-14	14030-14040	depression	_
81-15	14041-14044	and	_
81-16	14045-14052	alcohol	_
81-17	14053-14063	dependence	_
81-18	14064-14065	,	_
81-19	14066-14068	as	_
81-20	14069-14073	well	_
81-21	14074-14076	as	_
81-22	14077-14078	a	_
81-23	14079-14088	rationale	_
81-24	14089-14092	for	_
81-25	14093-14096	the	_
81-26	14097-14106	treatment	_
81-27	14107-14115	approach	_
81-28	14116-14117	,	_
81-29	14118-14119	(	_
81-30	14120-14121	b	_
81-31	14122-14123	)	_
81-32	14124-14132	increase	_
81-33	14133-14141	patients	_
81-34	14142-14143	’	_
81-35	14144-14153	awareness	_
81-36	14154-14156	of	_
81-37	14157-14166	different	_
81-38	14167-14178	experiences	_
81-39	14179-14188	including	_
81-40	14189-14192	low	_
81-41	14193-14197	mood	_
81-42	14198-14201	and	_
81-43	14202-14210	cravings	_
81-44	14211-14212	,	_
81-45	14213-14214	(	_
81-46	14215-14216	c	_
81-47	14217-14218	)	_
81-48	14219-14223	help	_
81-49	14224-14231	clients	_
81-50	14232-14234	to	_
81-51	14235-14243	distance	_
81-52	14244-14254	themselves	_
81-53	14255-14259	from	_
81-54	14260-14271	challenging	_
81-55	14272-14283	experiences	_
81-56	14284-14285	,	_
81-57	14286-14289	e.g	_
81-58	14290-14291	.	_

Text=by focusing on their breathing, (d) help them to respond to pleasant and unpleasant sensations with acceptance, and (e) foster their sense of strength and self-efficacy by enduring negative experiences and withstanding behavioral impulses.
82-1	14292-14294	by	_
82-2	14295-14303	focusing	_
82-3	14304-14306	on	_
82-4	14307-14312	their	_
82-5	14313-14322	breathing	_
82-6	14323-14324	,	_
82-7	14325-14326	(	_
82-8	14327-14328	d	_
82-9	14329-14330	)	_
82-10	14331-14335	help	_
82-11	14336-14340	them	_
82-12	14341-14343	to	_
82-13	14344-14351	respond	_
82-14	14352-14354	to	_
82-15	14355-14363	pleasant	_
82-16	14364-14367	and	_
82-17	14368-14378	unpleasant	_
82-18	14379-14389	sensations	_
82-19	14390-14394	with	_
82-20	14395-14405	acceptance	_
82-21	14406-14407	,	_
82-22	14408-14411	and	_
82-23	14412-14413	(	_
82-24	14414-14415	e	_
82-25	14416-14417	)	_
82-26	14418-14424	foster	_
82-27	14425-14430	their	_
82-28	14431-14436	sense	_
82-29	14437-14439	of	_
82-30	14440-14448	strength	_
82-31	14449-14452	and	_
82-32	14453-14466	self-efficacy	_
82-33	14467-14469	by	_
82-34	14470-14478	enduring	_
82-35	14479-14487	negative	_
82-36	14488-14499	experiences	_
82-37	14500-14503	and	_
82-38	14504-14516	withstanding	_
82-39	14517-14527	behavioral	_
82-40	14528-14536	impulses	_
82-41	14537-14538	.	_

Text=Additional information The study protocol is in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines for reporting interventional trials.
83-1	14539-14549	Additional	_
83-2	14550-14561	information	_
83-3	14562-14565	The	_
83-4	14566-14571	study	_
83-5	14572-14580	protocol	_
83-6	14581-14583	is	_
83-7	14584-14586	in	_
83-8	14587-14597	accordance	_
83-9	14598-14602	with	_
83-10	14603-14606	the	_
83-11	14607-14615	Standard	_
83-12	14616-14624	Protocol	_
83-13	14625-14630	Items	_
83-14	14631-14632	:	_
83-15	14633-14648	Recommendations	_
83-16	14649-14652	for	_
83-17	14653-14667	Interventional	_
83-18	14668-14674	Trials	_
83-19	14675-14676	(	_
83-20	14677-14683	SPIRIT	_
83-21	14684-14685	)	_
83-22	14686-14696	guidelines	_
83-23	14697-14700	for	_
83-24	14701-14710	reporting	_
83-25	14711-14725	interventional	_
83-26	14726-14732	trials	_
83-27	14733-14734	.	_

Text=Ethical approval and consent has been obtained by the leading ethics committee of the Medical Faculty Mannheim/University of Heidelberg (reference number: 2015-606 N-MA).
84-1	14735-14742	Ethical	_
84-2	14743-14751	approval	_
84-3	14752-14755	and	_
84-4	14756-14763	consent	_
84-5	14764-14767	has	_
84-6	14768-14772	been	_
84-7	14773-14781	obtained	_
84-8	14782-14784	by	_
84-9	14785-14788	the	_
84-10	14789-14796	leading	_
84-11	14797-14803	ethics	_
84-12	14804-14813	committee	_
84-13	14814-14816	of	_
84-14	14817-14820	the	_
84-15	14821-14828	Medical	_
84-16	14829-14836	Faculty	_
84-17	14837-14856	Mannheim/University	_
84-18	14857-14859	of	_
84-19	14860-14870	Heidelberg	_
84-20	14871-14872	(	_
84-21	14873-14882	reference	_
84-22	14883-14889	number	_
84-23	14890-14891	:	_
84-24	14892-14900	2015-606	_
84-25	14901-14905	N-MA	_
84-26	14906-14907	)	_
84-27	14908-14909	.	_

Text=The study will be conducted in compliance with the guidelines for Good Clinical Practice and the Declaration of Helsinki.
85-1	14910-14913	The	_
85-2	14914-14919	study	_
85-3	14920-14924	will	_
85-4	14925-14927	be	_
85-5	14928-14937	conducted	_
85-6	14938-14940	in	_
85-7	14941-14951	compliance	_
85-8	14952-14956	with	_
85-9	14957-14960	the	_
85-10	14961-14971	guidelines	_
85-11	14972-14975	for	_
85-12	14976-14980	Good	_
85-13	14981-14989	Clinical	_
85-14	14990-14998	Practice	_
85-15	14999-15002	and	_
85-16	15003-15006	the	_
85-17	15007-15018	Declaration	_
85-18	15019-15021	of	_
85-19	15022-15030	Helsinki	_
85-20	15031-15032	.	_

Text=Participants will provide informed consent prior to enrolment in the study.
86-1	15033-15045	Participants	_
86-2	15046-15050	will	_
86-3	15051-15058	provide	_
86-4	15059-15067	informed	_
86-5	15068-15075	consent	_
86-6	15076-15081	prior	_
86-7	15082-15084	to	_
86-8	15085-15094	enrolment	_
86-9	15095-15097	in	_
86-10	15098-15101	the	_
86-11	15102-15107	study	_
86-12	15108-15109	.	_

Text=The trial is registered in the German Clinical Trial Registration (DRKS00010249).
87-1	15110-15113	The	_
87-2	15114-15119	trial	_
87-3	15120-15122	is	_
87-4	15123-15133	registered	_
87-5	15134-15136	in	_
87-6	15137-15140	the	_
87-7	15141-15147	German	_
87-8	15148-15156	Clinical	_
87-9	15157-15162	Trial	_
87-10	15163-15175	Registration	_
87-11	15176-15177	(	_
87-12	15178-15190	DRKS00010249	_
87-13	15191-15192	)	_
87-14	15193-15194	.	_

Text=Any changes to the protocol will be described in this trial registry.
88-1	15195-15198	Any	_
88-2	15199-15206	changes	_
88-3	15207-15209	to	_
88-4	15210-15213	the	_
88-5	15214-15222	protocol	_
88-6	15223-15227	will	_
88-7	15228-15230	be	_
88-8	15231-15240	described	_
88-9	15241-15243	in	_
88-10	15244-15248	this	_
88-11	15249-15254	trial	_
88-12	15255-15263	registry	_
88-13	15264-15265	.	_

Text=The principal investigator (PK), independent from the sponsor and with no competing interests to report, is responsible for data monitoring.
89-1	15266-15269	The	_
89-2	15270-15279	principal	_
89-3	15280-15292	investigator	_
89-4	15293-15294	(	_
89-5	15295-15297	PK	_
89-6	15298-15299	)	_
89-7	15300-15301	,	_
89-8	15302-15313	independent	_
89-9	15314-15318	from	_
89-10	15319-15322	the	_
89-11	15323-15330	sponsor	_
89-12	15331-15334	and	_
89-13	15335-15339	with	_
89-14	15340-15342	no	_
89-15	15343-15352	competing	_
89-16	15353-15362	interests	_
89-17	15363-15365	to	_
89-18	15366-15372	report	_
89-19	15373-15374	,	_
89-20	15375-15377	is	_
89-21	15378-15389	responsible	_
89-22	15390-15393	for	_
89-23	15394-15398	data	_
89-24	15399-15409	monitoring	_
89-25	15410-15411	.	_

Text=All adverse events are documented.
90-1	15412-15415	All	_
90-2	15416-15423	adverse	_
90-3	15424-15430	events	_
90-4	15431-15434	are	_
90-5	15435-15445	documented	_
90-6	15446-15447	.	_

Text=Interim analyzes are not planned but cross-sectional comparisons for T1 data will be conducted after inclusion of all T1 participants and before data collections at T2 and FU are completed.
91-1	15448-15455	Interim	_
91-2	15456-15464	analyzes	_
91-3	15465-15468	are	_
91-4	15469-15472	not	_
91-5	15473-15480	planned	_
91-6	15481-15484	but	_
91-7	15485-15500	cross-sectional	_
91-8	15501-15512	comparisons	_
91-9	15513-15516	for	_
91-10	15517-15519	T1	_
91-11	15520-15524	data	_
91-12	15525-15529	will	_
91-13	15530-15532	be	_
91-14	15533-15542	conducted	_
91-15	15543-15548	after	_
91-16	15549-15558	inclusion	_
91-17	15559-15561	of	_
91-18	15562-15565	all	_
91-19	15566-15568	T1	_
91-20	15569-15581	participants	_
91-21	15582-15585	and	_
91-22	15586-15592	before	_
91-23	15593-15597	data	_
91-24	15598-15609	collections	_
91-25	15610-15612	at	_
91-26	15613-15615	T2	_
91-27	15616-15619	and	_
91-28	15620-15622	FU	_
91-29	15623-15626	are	_
91-30	15627-15636	completed	_
91-31	15637-15638	.	_

Text=The day-to-day management of the study (e.g.
92-1	15639-15642	The	_
92-2	15643-15653	day-to-day	_
92-3	15654-15664	management	_
92-4	15665-15667	of	_
92-5	15668-15671	the	_
92-6	15672-15677	study	_
92-7	15678-15679	(	_
92-8	15680-15683	e.g	_
92-9	15684-15685	.	_

Text=contact with the participants and the invitation to conduct online surveys) is carried out by advanced researchers.
93-1	15686-15693	contact	_
93-2	15694-15698	with	_
93-3	15699-15702	the	_
93-4	15703-15715	participants	_
93-5	15716-15719	and	_
93-6	15720-15723	the	_
93-7	15724-15734	invitation	_
93-8	15735-15737	to	_
93-9	15738-15745	conduct	_
93-10	15746-15752	online	_
93-11	15753-15760	surveys	_
93-12	15761-15762	)	_
93-13	15763-15765	is	_
93-14	15766-15773	carried	_
93-15	15774-15777	out	_
93-16	15778-15780	by	_
93-17	15781-15789	advanced	_
93-18	15790-15801	researchers	_
93-19	15802-15803	.	_

Text=The publication of the results will be independent of the results of the study, even if the intervention proves to have no influence on brain activation and connectivity.
94-1	15804-15807	The	_
94-2	15808-15819	publication	_
94-3	15820-15822	of	_
94-4	15823-15826	the	_
94-5	15827-15834	results	_
94-6	15835-15839	will	_
94-7	15840-15842	be	_
94-8	15843-15854	independent	_
94-9	15855-15857	of	_
94-10	15858-15861	the	_
94-11	15862-15869	results	_
94-12	15870-15872	of	_
94-13	15873-15876	the	_
94-14	15877-15882	study	_
94-15	15883-15884	,	_
94-16	15885-15889	even	_
94-17	15890-15892	if	_
94-18	15893-15896	the	_
94-19	15897-15909	intervention	_
94-20	15910-15916	proves	_
94-21	15917-15919	to	_
94-22	15920-15924	have	_
94-23	15925-15927	no	_
94-24	15928-15937	influence	_
94-25	15938-15940	on	_
94-26	15941-15946	brain	_
94-27	15947-15957	activation	_
94-28	15958-15961	and	_
94-29	15962-15974	connectivity	_
94-30	15975-15976	.	_

Text=Authorship eligibility will be decided according to the guidelines for safeguarding good scientific practice provided be the German Research Association.
95-1	15977-15987	Authorship	_
95-2	15988-15999	eligibility	_
95-3	16000-16004	will	_
95-4	16005-16007	be	_
95-5	16008-16015	decided	_
95-6	16016-16025	according	_
95-7	16026-16028	to	_
95-8	16029-16032	the	_
95-9	16033-16043	guidelines	_
95-10	16044-16047	for	_
95-11	16048-16060	safeguarding	_
95-12	16061-16065	good	_
95-13	16066-16076	scientific	_
95-14	16077-16085	practice	_
95-15	16086-16094	provided	_
95-16	16095-16097	be	_
95-17	16098-16101	the	_
95-18	16102-16108	German	_
95-19	16109-16117	Research	_
95-20	16118-16129	Association	_
95-21	16130-16131	.	_

Text=A written summary of the results will also be made available to the participants after completion of the study.
96-1	16132-16133	A	_
96-2	16134-16141	written	_
96-3	16142-16149	summary	_
96-4	16150-16152	of	_
96-5	16153-16156	the	_
96-6	16157-16164	results	_
96-7	16165-16169	will	_
96-8	16170-16174	also	_
96-9	16175-16177	be	_
96-10	16178-16182	made	_
96-11	16183-16192	available	_
96-12	16193-16195	to	_
96-13	16196-16199	the	_
96-14	16200-16212	participants	_
96-15	16213-16218	after	_
96-16	16219-16229	completion	_
96-17	16230-16232	of	_
96-18	16233-16236	the	_
96-19	16237-16242	study	_
96-20	16243-16244	.	_

Text=Data, statistical parameters and statistical code of the study will be made accessible to interested researchers after request.
97-1	16245-16249	Data	_
97-2	16250-16251	,	_
97-3	16252-16263	statistical	_
97-4	16264-16274	parameters	_
97-5	16275-16278	and	_
97-6	16279-16290	statistical	_
97-7	16291-16295	code	_
97-8	16296-16298	of	_
97-9	16299-16302	the	_
97-10	16303-16308	study	_
97-11	16309-16313	will	_
97-12	16314-16316	be	_
97-13	16317-16321	made	_
97-14	16322-16332	accessible	_
97-15	16333-16335	to	_
97-16	16336-16346	interested	_
97-17	16347-16358	researchers	_
97-18	16359-16364	after	_
97-19	16365-16372	request	_
97-20	16373-16374	.	_

Text=Due to data safety concerns, raw data cannot made openly accessible for the public.
98-1	16375-16378	Due	_
98-2	16379-16381	to	_
98-3	16382-16386	data	_
98-4	16387-16393	safety	_
98-5	16394-16402	concerns	_
98-6	16403-16404	,	_
98-7	16405-16408	raw	_
98-8	16409-16413	data	_
98-9	16414-16417	can	_
98-10	16418-16421	not	_
98-11	16422-16426	made	_
98-12	16427-16433	openly	_
98-13	16434-16444	accessible	_
98-14	16445-16448	for	_
98-15	16449-16452	the	_
98-16	16453-16459	public	_
98-17	16460-16461	.	_

Text=fMRI assessment battery Reward paradigm In this event-related paradigm, participants are asked to respond to a flashlight as fast as possible by pressing a button.
99-1	16462-16466	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
99-2	16467-16477	assessment	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
99-3	16478-16485	battery	_
99-4	16486-16492	Reward	_
99-5	16493-16501	paradigm	http://maven.renci.org/NeuroBridge/neurobridge#SternbergItemRecognitionParadigmTask
99-6	16502-16504	In	_
99-7	16505-16509	this	_
99-8	16510-16523	event-related	_
99-9	16524-16532	paradigm	_
99-10	16533-16534	,	_
99-11	16535-16547	participants	_
99-12	16548-16551	are	_
99-13	16552-16557	asked	_
99-14	16558-16560	to	_
99-15	16561-16568	respond	_
99-16	16569-16571	to	_
99-17	16572-16573	a	_
99-18	16574-16584	flashlight	_
99-19	16585-16587	as	_
99-20	16588-16592	fast	_
99-21	16593-16595	as	_
99-22	16596-16604	possible	_
99-23	16605-16607	by	_
99-24	16608-16616	pressing	_
99-25	16617-16618	a	_
99-26	16619-16625	button	_
99-27	16626-16627	.	_

Text=Preceding the flashlight, an arrow cue informs the participant about the rewarding consequences of their response to the flash stimulus.
100-1	16628-16637	Preceding	_
100-2	16638-16641	the	_
100-3	16642-16652	flashlight	_
100-4	16653-16654	,	_
100-5	16655-16657	an	_
100-6	16658-16663	arrow	_
100-7	16664-16667	cue	_
100-8	16668-16675	informs	_
100-9	16676-16679	the	_
100-10	16680-16691	participant	_
100-11	16692-16697	about	_
100-12	16698-16701	the	_
100-13	16702-16711	rewarding	_
100-14	16712-16724	consequences	_
100-15	16725-16727	of	_
100-16	16728-16733	their	_
100-17	16734-16742	response	_
100-18	16743-16745	to	_
100-19	16746-16749	the	_
100-20	16750-16755	flash	_
100-21	16756-16764	stimulus	_
100-22	16765-16766	.	_

Text=Four conditions are included in the paradigm: (1) in the so called monetary reward condition (arrow up) participants ’ fast response to the flash is rewarded with 2€; (2) in the punishment avoidance condition (arrow down) a slow response is punished by a loss of 2€ while a fast response is rewarded by the avoidance of that loss; (3) the verbal feedback condition (vertical double arrow) allows the participants to receive verbal feedback on their performance; (4) in the passive control condition (horizontal double arrow) no response is required.
101-1	16767-16771	Four	_
101-2	16772-16782	conditions	_
101-3	16783-16786	are	_
101-4	16787-16795	included	_
101-5	16796-16798	in	_
101-6	16799-16802	the	_
101-7	16803-16811	paradigm	_
101-8	16812-16813	:	_
101-9	16814-16815	(	_
101-10	16816-16817	1	_
101-11	16818-16819	)	_
101-12	16820-16822	in	_
101-13	16823-16826	the	_
101-14	16827-16829	so	_
101-15	16830-16836	called	_
101-16	16837-16845	monetary	_
101-17	16846-16852	reward	_
101-18	16853-16862	condition	_
101-19	16863-16864	(	_
101-20	16865-16870	arrow	_
101-21	16871-16873	up	_
101-22	16874-16875	)	_
101-23	16876-16888	participants	_
101-24	16889-16890	’	_
101-25	16891-16895	fast	_
101-26	16896-16904	response	_
101-27	16905-16907	to	_
101-28	16908-16911	the	_
101-29	16912-16917	flash	_
101-30	16918-16920	is	_
101-31	16921-16929	rewarded	_
101-32	16930-16934	with	_
101-33	16935-16937	2€	_
101-34	16938-16939	;	_
101-35	16940-16941	(	_
101-36	16942-16943	2	_
101-37	16944-16945	)	_
101-38	16946-16948	in	_
101-39	16949-16952	the	_
101-40	16953-16963	punishment	_
101-41	16964-16973	avoidance	_
101-42	16974-16983	condition	_
101-43	16984-16985	(	_
101-44	16986-16991	arrow	_
101-45	16992-16996	down	_
101-46	16997-16998	)	_
101-47	16999-17000	a	_
101-48	17001-17005	slow	_
101-49	17006-17014	response	_
101-50	17015-17017	is	_
101-51	17018-17026	punished	_
101-52	17027-17029	by	_
101-53	17030-17031	a	_
101-54	17032-17036	loss	_
101-55	17037-17039	of	_
101-56	17040-17042	2€	_
101-57	17043-17048	while	_
101-58	17049-17050	a	_
101-59	17051-17055	fast	_
101-60	17056-17064	response	_
101-61	17065-17067	is	_
101-62	17068-17076	rewarded	_
101-63	17077-17079	by	_
101-64	17080-17083	the	_
101-65	17084-17093	avoidance	_
101-66	17094-17096	of	_
101-67	17097-17101	that	_
101-68	17102-17106	loss	_
101-69	17107-17108	;	_
101-70	17109-17110	(	_
101-71	17111-17112	3	_
101-72	17113-17114	)	_
101-73	17115-17118	the	_
101-74	17119-17125	verbal	_
101-75	17126-17134	feedback	_
101-76	17135-17144	condition	_
101-77	17145-17146	(	_
101-78	17147-17155	vertical	_
101-79	17156-17162	double	_
101-80	17163-17168	arrow	_
101-81	17169-17170	)	_
101-82	17171-17177	allows	_
101-83	17178-17181	the	_
101-84	17182-17194	participants	_
101-85	17195-17197	to	_
101-86	17198-17205	receive	_
101-87	17206-17212	verbal	_
101-88	17213-17221	feedback	_
101-89	17222-17224	on	_
101-90	17225-17230	their	_
101-91	17231-17242	performance	_
101-92	17243-17244	;	_
101-93	17245-17246	(	_
101-94	17247-17248	4	_
101-95	17249-17250	)	_
101-96	17251-17253	in	_
101-97	17254-17257	the	_
101-98	17258-17265	passive	_
101-99	17266-17273	control	_
101-100	17274-17283	condition	_
101-101	17284-17285	(	_
101-102	17286-17296	horizontal	_
101-103	17297-17303	double	_
101-104	17304-17309	arrow	_
101-105	17310-17311	)	_
101-106	17312-17314	no	_
101-107	17315-17323	response	_
101-108	17324-17326	is	_
101-109	17327-17335	required	_
101-110	17336-17337	.	_

Text=During the outcome phase, the participants see the reward of the latest trial (“ 2€ ”, “ 0″ or “ Fast response! ”, “ Too slow ”) as well as their cumulative total gain at that point in time.
102-1	17338-17344	During	_
102-2	17345-17348	the	_
102-3	17349-17356	outcome	_
102-4	17357-17362	phase	_
102-5	17363-17364	,	_
102-6	17365-17368	the	_
102-7	17369-17381	participants	_
102-8	17382-17385	see	_
102-9	17386-17389	the	_
102-10	17390-17396	reward	_
102-11	17397-17399	of	_
102-12	17400-17403	the	_
102-13	17404-17410	latest	_
102-14	17411-17416	trial	_
102-15	17417-17418	(	_
102-16	17419-17420	“	_
102-17	17421-17423	2€	_
102-18	17424-17425	”	_
102-19	17426-17427	,	_
102-20	17428-17429	“	_
102-21	17430-17432	0″	_
102-22	17433-17435	or	_
102-23	17436-17437	“	_
102-24	17438-17442	Fast	_
102-25	17443-17451	response	_
102-26	17452-17453	!	_
102-27	17454-17455	”	_
102-28	17456-17457	,	_
102-29	17458-17459	“	_
102-30	17460-17463	Too	_
102-31	17464-17468	slow	_
102-32	17469-17470	”	_
102-33	17471-17472	)	_
102-34	17473-17475	as	_
102-35	17476-17480	well	_
102-36	17481-17483	as	_
102-37	17484-17489	their	_
102-38	17490-17500	cumulative	_
102-39	17501-17506	total	_
102-40	17507-17511	gain	_
102-41	17512-17514	at	_
102-42	17515-17519	that	_
102-43	17520-17525	point	_
102-44	17526-17528	in	_
102-45	17529-17533	time	_
102-46	17534-17535	.	_

Text=In order to ensure that all participants are able to win some money and have comparable winnings, the threshold for a fast response is adaptively tailored for each trial to the individual response times of the subject.
103-1	17536-17538	In	_
103-2	17539-17544	order	_
103-3	17545-17547	to	_
103-4	17548-17554	ensure	_
103-5	17555-17559	that	_
103-6	17560-17563	all	_
103-7	17564-17576	participants	_
103-8	17577-17580	are	_
103-9	17581-17585	able	_
103-10	17586-17588	to	_
103-11	17589-17592	win	_
103-12	17593-17597	some	_
103-13	17598-17603	money	_
103-14	17604-17607	and	_
103-15	17608-17612	have	_
103-16	17613-17623	comparable	_
103-17	17624-17632	winnings	_
103-18	17633-17634	,	_
103-19	17635-17638	the	_
103-20	17639-17648	threshold	_
103-21	17649-17652	for	_
103-22	17653-17654	a	_
103-23	17655-17659	fast	_
103-24	17660-17668	response	_
103-25	17669-17671	is	_
103-26	17672-17682	adaptively	_
103-27	17683-17691	tailored	_
103-28	17692-17695	for	_
103-29	17696-17700	each	_
103-30	17701-17706	trial	_
103-31	17707-17709	to	_
103-32	17710-17713	the	_
103-33	17714-17724	individual	_
103-34	17725-17733	response	_
103-35	17734-17739	times	_
103-36	17740-17742	of	_
103-37	17743-17746	the	_
103-38	17747-17754	subject	_
103-39	17755-17756	.	_

Text=The inter-trial interval was randomly varied between 6 and 9 s. Each condition is presented 10 times in a pseudo-randomized trial order with no more than two equal conditions in succession.
104-1	17757-17760	The	_
104-2	17761-17772	inter-trial	_
104-3	17773-17781	interval	_
104-4	17782-17785	was	_
104-5	17786-17794	randomly	_
104-6	17795-17801	varied	_
104-7	17802-17809	between	_
104-8	17810-17811	6	_
104-9	17812-17815	and	_
104-10	17816-17817	9	_
104-11	17818-17820	s.	_
104-12	17821-17825	Each	_
104-13	17826-17835	condition	_
104-14	17836-17838	is	_
104-15	17839-17848	presented	_
104-16	17849-17851	10	_
104-17	17852-17857	times	_
104-18	17858-17860	in	_
104-19	17861-17862	a	_
104-20	17863-17880	pseudo-randomized	_
104-21	17881-17886	trial	_
104-22	17887-17892	order	_
104-23	17893-17897	with	_
104-24	17898-17900	no	_
104-25	17901-17905	more	_
104-26	17906-17910	than	_
104-27	17911-17914	two	_
104-28	17915-17920	equal	_
104-29	17921-17931	conditions	_
104-30	17932-17934	in	_
104-31	17935-17945	succession	_
104-32	17946-17947	.	_

Text=The total run length is 9 min.
105-1	17948-17951	The	_
105-2	17952-17957	total	_
105-3	17958-17961	run	_
105-4	17962-17968	length	_
105-5	17969-17971	is	_
105-6	17972-17973	9	_
105-7	17974-17977	min	_
105-8	17978-17979	.	_

Text=The monetary reward anticipation task has been shown to reliably and robustly activate the ventral striatum including the nucleus accumbens.
106-1	17980-17983	The	_
106-2	17984-17992	monetary	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale
106-3	17993-17999	reward	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale
106-4	18000-18012	anticipation	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale
106-5	18013-18017	task	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale
106-6	18018-18021	has	_
106-7	18022-18026	been	_
106-8	18027-18032	shown	_
106-9	18033-18035	to	_
106-10	18036-18044	reliably	_
106-11	18045-18048	and	_
106-12	18049-18057	robustly	_
106-13	18058-18066	activate	_
106-14	18067-18070	the	_
106-15	18071-18078	ventral	_
106-16	18079-18087	striatum	_
106-17	18088-18097	including	_
106-18	18098-18101	the	_
106-19	18102-18109	nucleus	_
106-20	18110-18119	accumbens	_
106-21	18120-18121	.	_

Text=Erotic incentive delay task In order to measure different categories of reward processing, a variant of our own monetary reward task comprising erotic stimuli will be performed.
107-1	18122-18128	Erotic	_
107-2	18129-18138	incentive	_
107-3	18139-18144	delay	_
107-4	18145-18149	task	_
107-5	18150-18152	In	_
107-6	18153-18158	order	_
107-7	18159-18161	to	_
107-8	18162-18169	measure	_
107-9	18170-18179	different	_
107-10	18180-18190	categories	_
107-11	18191-18193	of	_
107-12	18194-18200	reward	_
107-13	18201-18211	processing	_
107-14	18212-18213	,	_
107-15	18214-18215	a	_
107-16	18216-18223	variant	_
107-17	18224-18226	of	_
107-18	18227-18230	our	_
107-19	18231-18234	own	_
107-20	18235-18243	monetary	_
107-21	18244-18250	reward	_
107-22	18251-18255	task	_
107-23	18256-18266	comprising	_
107-24	18267-18273	erotic	_
107-25	18274-18281	stimuli	_
107-26	18282-18286	will	_
107-27	18287-18289	be	_
107-28	18290-18299	performed	_
107-29	18300-18301	.	_

Text=Similar to the description above, participants have to respond to a cued probe to receive either erotic stimuli or matched social control stimuli.
108-1	18302-18309	Similar	_
108-2	18310-18312	to	_
108-3	18313-18316	the	_
108-4	18317-18328	description	_
108-5	18329-18334	above	_
108-6	18335-18336	,	_
108-7	18337-18349	participants	_
108-8	18350-18354	have	_
108-9	18355-18357	to	_
108-10	18358-18365	respond	_
108-11	18366-18368	to	_
108-12	18369-18370	a	_
108-13	18371-18375	cued	_
108-14	18376-18381	probe	_
108-15	18382-18384	to	_
108-16	18385-18392	receive	_
108-17	18393-18399	either	_
108-18	18400-18406	erotic	_
108-19	18407-18414	stimuli	_
108-20	18415-18417	or	_
108-21	18418-18425	matched	_
108-22	18426-18432	social	_
108-23	18433-18440	control	_
108-24	18441-18448	stimuli	_
108-25	18449-18450	.	_

Text=Again during the anticipation phase, distinct cues preceding the target inform the participants whether a rewarding erotic image will be shown or not.
109-1	18451-18456	Again	_
109-2	18457-18463	during	_
109-3	18464-18467	the	_
109-4	18468-18480	anticipation	_
109-5	18481-18486	phase	_
109-6	18487-18488	,	_
109-7	18489-18497	distinct	_
109-8	18498-18502	cues	_
109-9	18503-18512	preceding	_
109-10	18513-18516	the	_
109-11	18517-18523	target	_
109-12	18524-18530	inform	_
109-13	18531-18534	the	_
109-14	18535-18547	participants	_
109-15	18548-18555	whether	_
109-16	18556-18557	a	_
109-17	18558-18567	rewarding	_
109-18	18568-18574	erotic	_
109-19	18575-18580	image	_
109-20	18581-18585	will	_
109-21	18586-18588	be	_
109-22	18589-18594	shown	_
109-23	18595-18597	or	_
109-24	18598-18601	not	_
109-25	18602-18603	.	_

Text=In previous studies it has been shown that striatal reward-associated brain activations can be reliably observed when erotic pictures are presented.
110-1	18604-18606	In	_
110-2	18607-18615	previous	_
110-3	18616-18623	studies	_
110-4	18624-18626	it	_
110-5	18627-18630	has	_
110-6	18631-18635	been	_
110-7	18636-18641	shown	_
110-8	18642-18646	that	_
110-9	18647-18655	striatal	_
110-10	18656-18673	reward-associated	_
110-11	18674-18679	brain	_
110-12	18680-18691	activations	_
110-13	18692-18695	can	_
110-14	18696-18698	be	_
110-15	18699-18707	reliably	_
110-16	18708-18716	observed	_
110-17	18717-18721	when	_
110-18	18722-18728	erotic	_
110-19	18729-18737	pictures	_
110-20	18738-18741	are	_
110-21	18742-18751	presented	_
110-22	18752-18753	.	_

Text=Resting state/mood induction paradigm The so called mood induction paradigm has been successfully implemented in different studies.
111-1	18754-18761	Resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
111-2	18762-18772	state/mood	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
111-3	18773-18782	induction	_
111-4	18783-18791	paradigm	_
111-5	18792-18795	The	_
111-6	18796-18798	so	_
111-7	18799-18805	called	_
111-8	18806-18810	mood	_
111-9	18811-18820	induction	_
111-10	18821-18829	paradigm	_
111-11	18830-18833	has	_
111-12	18834-18838	been	_
111-13	18839-18851	successfully	_
111-14	18852-18863	implemented	_
111-15	18864-18866	in	_
111-16	18867-18876	different	_
111-17	18877-18884	studies	_
111-18	18885-18886	.	_

Text=Here, we will use a modified version of the paradigm in order to directly test intervention associated activation and connectivity patterns.
112-1	18887-18891	Here	_
112-2	18892-18893	,	_
112-3	18894-18896	we	_
112-4	18897-18901	will	_
112-5	18902-18905	use	_
112-6	18906-18907	a	_
112-7	18908-18916	modified	_
112-8	18917-18924	version	_
112-9	18925-18927	of	_
112-10	18928-18931	the	_
112-11	18932-18940	paradigm	_
112-12	18941-18943	in	_
112-13	18944-18949	order	_
112-14	18950-18952	to	_
112-15	18953-18961	directly	_
112-16	18962-18966	test	_
112-17	18967-18979	intervention	_
112-18	18980-18990	associated	_
112-19	18991-19001	activation	_
112-20	19002-19005	and	_
112-21	19006-19018	connectivity	_
112-22	19019-19027	patterns	_
112-23	19028-19029	.	_

Text=The paradigm consists of five blocks, each of which lasts 4.5 min: a resting state block, a sad mood induction block, one alcohol cue-reactivity block, one mindfulness-based block and one behavioral activation block.
113-1	19030-19033	The	_
113-2	19034-19042	paradigm	_
113-3	19043-19051	consists	_
113-4	19052-19054	of	_
113-5	19055-19059	five	_
113-6	19060-19066	blocks	_
113-7	19067-19068	,	_
113-8	19069-19073	each	_
113-9	19074-19076	of	_
113-10	19077-19082	which	_
113-11	19083-19088	lasts	_
113-12	19089-19092	4.5	_
113-13	19093-19096	min	_
113-14	19097-19098	:	_
113-15	19099-19100	a	_
113-16	19101-19108	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
113-17	19109-19114	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
113-18	19115-19120	block	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
113-19	19121-19122	,	_
113-20	19123-19124	a	_
113-21	19125-19128	sad	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
113-22	19129-19133	mood	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
113-23	19134-19143	induction	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
113-24	19144-19149	block	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
113-25	19150-19151	,	_
113-26	19152-19155	one	_
113-27	19156-19163	alcohol	_
113-28	19164-19178	cue-reactivity	_
113-29	19179-19184	block	http://maven.renci.org/NeuroBridge/neurobridge#Location
113-30	19185-19186	,	_
113-31	19187-19190	one	_
113-32	19191-19208	mindfulness-based	_
113-33	19209-19214	block	http://maven.renci.org/NeuroBridge/neurobridge#Location
113-34	19215-19218	and	_
113-35	19219-19222	one	_
113-36	19223-19233	behavioral	_
113-37	19234-19244	activation	_
113-38	19245-19250	block	http://maven.renci.org/NeuroBridge/neurobridge#Location
113-39	19251-19252	.	_

Text=The mindfulness-based block and the behavioral activation block are counterbalanced.
114-1	19253-19256	The	_
114-2	19257-19274	mindfulness-based	_
114-3	19275-19280	block	_
114-4	19281-19284	and	_
114-5	19285-19288	the	_
114-6	19289-19299	behavioral	_
114-7	19300-19310	activation	_
114-8	19311-19316	block	_
114-9	19317-19320	are	_
114-10	19321-19336	counterbalanced	_
114-11	19337-19338	.	_

Text=During the resting state phase, participants are told to keep their eyes open and background pink noise is presented.
115-1	19339-19345	During	_
115-2	19346-19349	the	_
115-3	19350-19357	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
115-4	19358-19363	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
115-5	19364-19369	phase	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
115-6	19370-19371	,	_
115-7	19372-19384	participants	_
115-8	19385-19388	are	_
115-9	19389-19393	told	_
115-10	19394-19396	to	_
115-11	19397-19401	keep	_
115-12	19402-19407	their	_
115-13	19408-19412	eyes	_
115-14	19413-19417	open	_
115-15	19418-19421	and	_
115-16	19422-19432	background	_
115-17	19433-19437	pink	_
115-18	19438-19443	noise	_
115-19	19444-19446	is	_
115-20	19447-19456	presented	_
115-21	19457-19458	.	_

Text=During the sad mood induction phase, key words to remind participants of personal negative life events and background sad music (excerpt from Albinoni/Giazotto, Adagio in g-minor) are presented.
116-1	19459-19465	During	_
116-2	19466-19469	the	_
116-3	19470-19473	sad	_
116-4	19474-19478	mood	_
116-5	19479-19488	induction	_
116-6	19489-19494	phase	_
116-7	19495-19496	,	_
116-8	19497-19500	key	_
116-9	19501-19506	words	_
116-10	19507-19509	to	_
116-11	19510-19516	remind	_
116-12	19517-19529	participants	_
116-13	19530-19532	of	_
116-14	19533-19541	personal	_
116-15	19542-19550	negative	_
116-16	19551-19555	life	_
116-17	19556-19562	events	_
116-18	19563-19566	and	_
116-19	19567-19577	background	_
116-20	19578-19581	sad	_
116-21	19582-19587	music	_
116-22	19588-19589	(	_
116-23	19590-19597	excerpt	_
116-24	19598-19602	from	_
116-25	19603-19620	Albinoni/Giazotto	_
116-26	19621-19622	,	_
116-27	19623-19629	Adagio	_
116-28	19630-19632	in	_
116-29	19633-19640	g-minor	_
116-30	19641-19642	)	_
116-31	19643-19646	are	_
116-32	19647-19656	presented	_
116-33	19657-19658	.	_

Text=Participants are asked to concentrate on the negative life events and empathize with the situation.
117-1	19659-19671	Participants	_
117-2	19672-19675	are	_
117-3	19676-19681	asked	_
117-4	19682-19684	to	_
117-5	19685-19696	concentrate	_
117-6	19697-19699	on	_
117-7	19700-19703	the	_
117-8	19704-19712	negative	_
117-9	19713-19717	life	_
117-10	19718-19724	events	_
117-11	19725-19728	and	_
117-12	19729-19738	empathize	_
117-13	19739-19743	with	_
117-14	19744-19747	the	_
117-15	19748-19757	situation	_
117-16	19758-19759	.	_

Text=During the alcohol cue-reactivity phase, participants are presented images of either beer or wine (depending on the participants preference) while they receive corresponding audio induction statements instructing them to imagine alcohol-associated situations.
118-1	19760-19766	During	_
118-2	19767-19770	the	_
118-3	19771-19778	alcohol	_
118-4	19779-19793	cue-reactivity	_
118-5	19794-19799	phase	_
118-6	19800-19801	,	_
118-7	19802-19814	participants	_
118-8	19815-19818	are	_
118-9	19819-19828	presented	_
118-10	19829-19835	images	_
118-11	19836-19838	of	_
118-12	19839-19845	either	_
118-13	19846-19850	beer	_
118-14	19851-19853	or	_
118-15	19854-19858	wine	_
118-16	19859-19860	(	_
118-17	19861-19870	depending	_
118-18	19871-19873	on	_
118-19	19874-19877	the	_
118-20	19878-19890	participants	_
118-21	19891-19901	preference	_
118-22	19902-19903	)	_
118-23	19904-19909	while	_
118-24	19910-19914	they	_
118-25	19915-19922	receive	_
118-26	19923-19936	corresponding	_
118-27	19937-19942	audio	_
118-28	19943-19952	induction	_
118-29	19953-19963	statements	_
118-30	19964-19975	instructing	_
118-31	19976-19980	them	_
118-32	19981-19983	to	_
118-33	19984-19991	imagine	_
118-34	19992-20010	alcohol-associated	_
118-35	20011-20021	situations	_
118-36	20022-20023	.	_

Text=In the mindfulness- based phase, again, participants are presented images of beer or wine while this time they listen to mindfulness-based audio instructions.
119-1	20024-20026	In	_
119-2	20027-20030	the	_
119-3	20031-20043	mindfulness-	_
119-4	20044-20049	based	_
119-5	20050-20055	phase	_
119-6	20056-20057	,	_
119-7	20058-20063	again	_
119-8	20064-20065	,	_
119-9	20066-20078	participants	_
119-10	20079-20082	are	_
119-11	20083-20092	presented	_
119-12	20093-20099	images	_
119-13	20100-20102	of	_
119-14	20103-20107	beer	_
119-15	20108-20110	or	_
119-16	20111-20115	wine	_
119-17	20116-20121	while	_
119-18	20122-20126	this	_
119-19	20127-20131	time	_
119-20	20132-20136	they	_
119-21	20137-20143	listen	_
119-22	20144-20146	to	_
119-23	20147-20164	mindfulness-based	_
119-24	20165-20170	audio	_
119-25	20171-20183	instructions	_
119-26	20184-20185	.	_

Text=Correspondingly, in the behavioral activation training phase, participants are played audio instructions associated with imagining activities while viewing alcohol-associated pictures.
120-1	20186-20201	Correspondingly	_
120-2	20202-20203	,	_
120-3	20204-20206	in	_
120-4	20207-20210	the	_
120-5	20211-20221	behavioral	_
120-6	20222-20232	activation	_
120-7	20233-20241	training	_
120-8	20242-20247	phase	_
120-9	20248-20249	,	_
120-10	20250-20262	participants	_
120-11	20263-20266	are	_
120-12	20267-20273	played	_
120-13	20274-20279	audio	_
120-14	20280-20292	instructions	_
120-15	20293-20303	associated	_
120-16	20304-20308	with	_
120-17	20309-20318	imagining	_
120-18	20319-20329	activities	_
120-19	20330-20335	while	_
120-20	20336-20343	viewing	_
120-21	20344-20362	alcohol-associated	_
120-22	20363-20371	pictures	_
120-23	20372-20373	.	_

Text=In each phase, 9 alcohol-associated cues are presented for 15 s, while simultaneously 9 audio statements are played.
121-1	20374-20376	In	_
121-2	20377-20381	each	_
121-3	20382-20387	phase	_
121-4	20388-20389	,	_
121-5	20390-20391	9	_
121-6	20392-20410	alcohol-associated	_
121-7	20411-20415	cues	_
121-8	20416-20419	are	_
121-9	20420-20429	presented	_
121-10	20430-20433	for	_
121-11	20434-20436	15	_
121-12	20437-20438	s	_
121-13	20439-20440	,	_
121-14	20441-20446	while	_
121-15	20447-20461	simultaneously	_
121-16	20462-20463	9	_
121-17	20464-20469	audio	_
121-18	20470-20480	statements	_
121-19	20481-20484	are	_
121-20	20485-20491	played	_
121-21	20492-20493	.	_

Text=After each picture a fixation cross is presented for also 15 s. After each block, participants are instructed to rate their mood by means of the Positive and Negative Affect Schedule (PANAS), as well as their craving and self-control to abstain.
122-1	20494-20499	After	_
122-2	20500-20504	each	_
122-3	20505-20512	picture	_
122-4	20513-20514	a	_
122-5	20515-20523	fixation	_
122-6	20524-20529	cross	_
122-7	20530-20532	is	_
122-8	20533-20542	presented	_
122-9	20543-20546	for	_
122-10	20547-20551	also	_
122-11	20552-20554	15	_
122-12	20555-20557	s.	_
122-13	20558-20563	After	_
122-14	20564-20568	each	_
122-15	20569-20574	block	_
122-16	20575-20576	,	_
122-17	20577-20589	participants	_
122-18	20590-20593	are	_
122-19	20594-20604	instructed	_
122-20	20605-20607	to	_
122-21	20608-20612	rate	_
122-22	20613-20618	their	_
122-23	20619-20623	mood	_
122-24	20624-20626	by	_
122-25	20627-20632	means	_
122-26	20633-20635	of	_
122-27	20636-20639	the	_
122-28	20640-20648	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
122-29	20649-20652	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
122-30	20653-20661	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
122-31	20662-20668	Affect	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
122-32	20669-20677	Schedule	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
122-33	20678-20679	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
122-34	20680-20685	PANAS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
122-35	20686-20687	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
122-36	20688-20689	,	_
122-37	20690-20692	as	_
122-38	20693-20697	well	_
122-39	20698-20700	as	_
122-40	20701-20706	their	_
122-41	20707-20714	craving	_
122-42	20715-20718	and	_
122-43	20719-20731	self-control	_
122-44	20732-20734	to	_
122-45	20735-20742	abstain	_
122-46	20743-20744	.	_

Text=For the T2 assessment, a different set of alcohol-associated pictures is presented.
123-1	20745-20748	For	_
123-2	20749-20752	the	_
123-3	20753-20755	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
123-4	20756-20766	assessment	_
123-5	20767-20768	,	_
123-6	20769-20770	a	_
123-7	20771-20780	different	_
123-8	20781-20784	set	_
123-9	20785-20787	of	_
123-10	20788-20806	alcohol-associated	_
123-11	20807-20815	pictures	_
123-12	20816-20818	is	_
123-13	20819-20828	presented	_
123-14	20829-20830	.	_

Text=As mentioned above, the mindfulness-based block and the behavioral activation block are counterbalanced.
124-1	20831-20833	As	_
124-2	20834-20843	mentioned	_
124-3	20844-20849	above	_
124-4	20850-20851	,	_
124-5	20852-20855	the	_
124-6	20856-20873	mindfulness-based	_
124-7	20874-20879	block	_
124-8	20880-20883	and	_
124-9	20884-20887	the	_
124-10	20888-20898	behavioral	_
124-11	20899-20909	activation	_
124-12	20910-20915	block	_
124-13	20916-20919	are	_
124-14	20920-20935	counterbalanced	_
124-15	20936-20937	.	_

Text=Thus, a second randomization list will ensure that at T1 the order of the experimental blocks will be equally distributed above all participants.
125-1	20938-20942	Thus	_
125-2	20943-20944	,	_
125-3	20945-20946	a	_
125-4	20947-20953	second	_
125-5	20954-20967	randomization	_
125-6	20968-20972	list	_
125-7	20973-20977	will	_
125-8	20978-20984	ensure	_
125-9	20985-20989	that	_
125-10	20990-20992	at	_
125-11	20993-20995	T1	_
125-12	20996-20999	the	_
125-13	21000-21005	order	_
125-14	21006-21008	of	_
125-15	21009-21012	the	_
125-16	21013-21025	experimental	_
125-17	21026-21032	blocks	_
125-18	21033-21037	will	_
125-19	21038-21040	be	_
125-20	21041-21048	equally	_
125-21	21049-21060	distributed	_
125-22	21061-21066	above	_
125-23	21067-21070	all	_
125-24	21071-21083	participants	_
125-25	21084-21085	.	_

Text=Comorbid patients will receive the reverse order of their T1 assessment at the T2 fMRI scanning.
126-1	21086-21094	Comorbid	_
126-2	21095-21103	patients	_
126-3	21104-21108	will	_
126-4	21109-21116	receive	_
126-5	21117-21120	the	_
126-6	21121-21128	reverse	_
126-7	21129-21134	order	_
126-8	21135-21137	of	_
126-9	21138-21143	their	_
126-10	21144-21146	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
126-11	21147-21157	assessment	_
126-12	21158-21160	at	_
126-13	21161-21164	the	_
126-14	21165-21167	T2	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
126-15	21168-21172	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
126-16	21173-21181	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
126-17	21182-21183	.	_

Text=Anatomical image In order to assess the individual brain morphology of each participant, high-resolution T1-weighted anatomical images (MPRAGE) will be collected.
127-1	21184-21194	Anatomical	_
127-2	21195-21200	image	_
127-3	21201-21203	In	_
127-4	21204-21209	order	_
127-5	21210-21212	to	_
127-6	21213-21219	assess	_
127-7	21220-21223	the	_
127-8	21224-21234	individual	_
127-9	21235-21240	brain	_
127-10	21241-21251	morphology	_
127-11	21252-21254	of	_
127-12	21255-21259	each	_
127-13	21260-21271	participant	_
127-14	21272-21273	,	_
127-15	21274-21289	high-resolution	_
127-16	21290-21301	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
127-17	21302-21312	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
127-18	21313-21319	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
127-19	21320-21321	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
127-20	21322-21328	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
127-21	21329-21330	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
127-22	21331-21335	will	_
127-23	21336-21338	be	_
127-24	21339-21348	collected	_
127-25	21349-21350	.	_

Text=Primary outcome In this study, neural activation and connectivity in the reward system and default mode network are the primary outcome measures.
128-1	21351-21358	Primary	_
128-2	21359-21366	outcome	_
128-3	21367-21369	In	_
128-4	21370-21374	this	_
128-5	21375-21380	study	_
128-6	21381-21382	,	_
128-7	21383-21389	neural	_
128-8	21390-21400	activation	_
128-9	21401-21404	and	_
128-10	21405-21417	connectivity	_
128-11	21418-21420	in	_
128-12	21421-21424	the	_
128-13	21425-21431	reward	_
128-14	21432-21438	system	_
128-15	21439-21442	and	_
128-16	21443-21450	default	_
128-17	21451-21455	mode	_
128-18	21456-21463	network	_
128-19	21464-21467	are	_
128-20	21468-21471	the	_
128-21	21472-21479	primary	_
128-22	21480-21487	outcome	_
128-23	21488-21496	measures	_
128-24	21497-21498	.	_

Text=Neural correlates of reward and emotion processing in patients and healthy controls will be assessed by means of fMRI.
129-1	21499-21505	Neural	_
129-2	21506-21516	correlates	_
129-3	21517-21519	of	_
129-4	21520-21526	reward	_
129-5	21527-21530	and	_
129-6	21531-21538	emotion	_
129-7	21539-21549	processing	_
129-8	21550-21552	in	_
129-9	21553-21561	patients	_
129-10	21562-21565	and	_
129-11	21566-21573	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
129-12	21574-21582	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
129-13	21583-21587	will	_
129-14	21588-21590	be	_
129-15	21591-21599	assessed	_
129-16	21600-21602	by	_
129-17	21603-21608	means	_
129-18	21609-21611	of	_
129-19	21612-21616	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
129-20	21617-21618	.	_

Text=While the first measurement will identify common and/or distinct neural signatures underlying the comorbidity of alcohol dependence and depression, the second measurement allows investigating the influence of the psychotherapeutic interventions on these target brain mechanisms.
130-1	21619-21624	While	_
130-2	21625-21628	the	_
130-3	21629-21634	first	_
130-4	21635-21646	measurement	_
130-5	21647-21651	will	_
130-6	21652-21660	identify	_
130-7	21661-21667	common	_
130-8	21668-21674	and/or	_
130-9	21675-21683	distinct	_
130-10	21684-21690	neural	_
130-11	21691-21701	signatures	_
130-12	21702-21712	underlying	_
130-13	21713-21716	the	_
130-14	21717-21728	comorbidity	_
130-15	21729-21731	of	_
130-16	21732-21739	alcohol	_
130-17	21740-21750	dependence	_
130-18	21751-21754	and	_
130-19	21755-21765	depression	_
130-20	21766-21767	,	_
130-21	21768-21771	the	_
130-22	21772-21778	second	_
130-23	21779-21790	measurement	_
130-24	21791-21797	allows	_
130-25	21798-21811	investigating	_
130-26	21812-21815	the	_
130-27	21816-21825	influence	_
130-28	21826-21828	of	_
130-29	21829-21832	the	_
130-30	21833-21850	psychotherapeutic	_
130-31	21851-21864	interventions	_
130-32	21865-21867	on	_
130-33	21868-21873	these	_
130-34	21874-21880	target	_
130-35	21881-21886	brain	_
130-36	21887-21897	mechanisms	_
130-37	21898-21899	.	_

Text=Secondary outcome measures Secondary outcome measures include craving and depression scores, as well as relapse rates.
131-1	21900-21909	Secondary	_
131-2	21910-21917	outcome	_
131-3	21918-21926	measures	_
131-4	21927-21936	Secondary	_
131-5	21937-21944	outcome	_
131-6	21945-21953	measures	_
131-7	21954-21961	include	_
131-8	21962-21969	craving	_
131-9	21970-21973	and	_
131-10	21974-21984	depression	_
131-11	21985-21991	scores	_
131-12	21992-21993	,	_
131-13	21994-21996	as	_
131-14	21997-22001	well	_
131-15	22002-22004	as	_
131-16	22005-22012	relapse	_
131-17	22013-22018	rates	_
131-18	22019-22020	.	_

Text=Predictors Predictors include participants ’ characteristics and personality traits as assessed by questionnaires (See Table 1), as well as ratings before, during and after scanning.
132-1	22021-22031	Predictors	_
132-2	22032-22042	Predictors	_
132-3	22043-22050	include	_
132-4	22051-22063	participants	_
132-5	22064-22065	’	_
132-6	22066-22081	characteristics	_
132-7	22082-22085	and	_
132-8	22086-22097	personality	_
132-9	22098-22104	traits	_
132-10	22105-22107	as	_
132-11	22108-22116	assessed	_
132-12	22117-22119	by	_
132-13	22120-22134	questionnaires	_
132-14	22135-22136	(	_
132-15	22137-22140	See	_
132-16	22141-22146	Table	_
132-17	22147-22148	1	_
132-18	22149-22150	)	_
132-19	22151-22152	,	_
132-20	22153-22155	as	_
132-21	22156-22160	well	_
132-22	22161-22163	as	_
132-23	22164-22171	ratings	_
132-24	22172-22178	before	_
132-25	22179-22180	,	_
132-26	22181-22187	during	_
132-27	22188-22191	and	_
132-28	22192-22197	after	_
132-29	22198-22206	scanning	_
132-30	22207-22208	.	_

Text=Data analyses plan Analyses will be conducted on an intention to treat and treatment completers principle.
133-1	22209-22213	Data	_
133-2	22214-22222	analyses	_
133-3	22223-22227	plan	_
133-4	22228-22236	Analyses	_
133-5	22237-22241	will	_
133-6	22242-22244	be	_
133-7	22245-22254	conducted	_
133-8	22255-22257	on	_
133-9	22258-22260	an	_
133-10	22261-22270	intention	_
133-11	22271-22273	to	_
133-12	22274-22279	treat	_
133-13	22280-22283	and	_
133-14	22284-22293	treatment	_
133-15	22294-22304	completers	_
133-16	22305-22314	principle	_
133-17	22315-22316	.	_

Text=Behavioral data analyses Analysis will be completed by using (repeated measures) analysis of variance (AN (C) OVA) in order to test group differences (AUD vs MD vs Co vs HC) and treatment groups (BAT vs MBT).
134-1	22317-22327	Behavioral	_
134-2	22328-22332	data	_
134-3	22333-22341	analyses	_
134-4	22342-22350	Analysis	_
134-5	22351-22355	will	_
134-6	22356-22358	be	_
134-7	22359-22368	completed	_
134-8	22369-22371	by	_
134-9	22372-22377	using	_
134-10	22378-22379	(	_
134-11	22380-22388	repeated	_
134-12	22389-22397	measures	_
134-13	22398-22399	)	_
134-14	22400-22408	analysis	_
134-15	22409-22411	of	_
134-16	22412-22420	variance	_
134-17	22421-22422	(	_
134-18	22423-22425	AN	_
134-19	22426-22427	(	_
134-20	22428-22429	C	_
134-21	22430-22431	)	_
134-22	22432-22435	OVA	_
134-23	22436-22437	)	_
134-24	22438-22440	in	_
134-25	22441-22446	order	_
134-26	22447-22449	to	_
134-27	22450-22454	test	_
134-28	22455-22460	group	_
134-29	22461-22472	differences	_
134-30	22473-22474	(	_
134-31	22475-22478	AUD	_
134-32	22479-22481	vs	_
134-33	22482-22484	MD	_
134-34	22485-22487	vs	_
134-35	22488-22490	Co	_
134-36	22491-22493	vs	_
134-37	22494-22496	HC	_
134-38	22497-22498	)	_
134-39	22499-22502	and	_
134-40	22503-22512	treatment	_
134-41	22513-22519	groups	_
134-42	22520-22521	(	_
134-43	22522-22525	BAT	_
134-44	22526-22528	vs	_
134-45	22529-22532	MBT	_
134-46	22533-22534	)	_
134-47	22535-22536	.	_

Text=Difference scores will be calculated.
135-1	22537-22547	Difference	_
135-2	22548-22554	scores	_
135-3	22555-22559	will	_
135-4	22560-22562	be	_
135-5	22563-22573	calculated	_
135-6	22574-22575	.	_

Text=All measures will be compared between groups, as well as treatment groups and interaction effects will be explored.
136-1	22576-22579	All	_
136-2	22580-22588	measures	_
136-3	22589-22593	will	_
136-4	22594-22596	be	_
136-5	22597-22605	compared	_
136-6	22606-22613	between	_
136-7	22614-22620	groups	_
136-8	22621-22622	,	_
136-9	22623-22625	as	_
136-10	22626-22630	well	_
136-11	22631-22633	as	_
136-12	22634-22643	treatment	_
136-13	22644-22650	groups	_
136-14	22651-22654	and	_
136-15	22655-22666	interaction	_
136-16	22667-22674	effects	_
136-17	22675-22679	will	_
136-18	22680-22682	be	_
136-19	22683-22691	explored	_
136-20	22692-22693	.	_

Text=Wherever appropriate, missing data will be imputed using multiple imputation.
137-1	22694-22702	Wherever	_
137-2	22703-22714	appropriate	_
137-3	22715-22716	,	_
137-4	22717-22724	missing	_
137-5	22725-22729	data	_
137-6	22730-22734	will	_
137-7	22735-22737	be	_
137-8	22738-22745	imputed	_
137-9	22746-22751	using	_
137-10	22752-22760	multiple	_
137-11	22761-22771	imputation	_
137-12	22772-22773	.	_

Text=Activation fMRI analysis Preprocessing as well as statistical analyses of the experimental fMRI paradigms will be performed using SPM 12 (Wellcome Department of Cognitive Neurology, London, UK).
138-1	22774-22784	Activation	_
138-2	22785-22789	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
138-3	22790-22798	analysis	_
138-4	22799-22812	Preprocessing	_
138-5	22813-22815	as	_
138-6	22816-22820	well	_
138-7	22821-22823	as	_
138-8	22824-22835	statistical	_
138-9	22836-22844	analyses	_
138-10	22845-22847	of	_
138-11	22848-22851	the	_
138-12	22852-22864	experimental	_
138-13	22865-22869	fMRI	_
138-14	22870-22879	paradigms	_
138-15	22880-22884	will	_
138-16	22885-22887	be	_
138-17	22888-22897	performed	_
138-18	22898-22903	using	_
138-19	22904-22907	SPM	_
138-20	22908-22910	12	_
138-21	22911-22912	(	_
138-22	22913-22921	Wellcome	_
138-23	22922-22932	Department	_
138-24	22933-22935	of	_
138-25	22936-22945	Cognitive	_
138-26	22946-22955	Neurology	_
138-27	22956-22957	,	_
138-28	22958-22964	London	_
138-29	22965-22966	,	_
138-30	22967-22969	UK	_
138-31	22970-22971	)	_
138-32	22972-22973	.	_

Text=In order to reduce systematic motion-related artifacts known to be especially prevalent in patient-control studies, we use the ART toolbox (http: //www.nitrc.org/projects/artifact_detect) to detect outlier volumes.
139-1	22974-22976	In	_
139-2	22977-22982	order	_
139-3	22983-22985	to	_
139-4	22986-22992	reduce	_
139-5	22993-23003	systematic	_
139-6	23004-23018	motion-related	_
139-7	23019-23028	artifacts	_
139-8	23029-23034	known	_
139-9	23035-23037	to	_
139-10	23038-23040	be	_
139-11	23041-23051	especially	_
139-12	23052-23061	prevalent	_
139-13	23062-23064	in	_
139-14	23065-23080	patient-control	_
139-15	23081-23088	studies	_
139-16	23089-23090	,	_
139-17	23091-23093	we	_
139-18	23094-23097	use	_
139-19	23098-23101	the	_
139-20	23102-23105	ART	_
139-21	23106-23113	toolbox	_
139-22	23114-23115	(	_
139-23	23116-23120	http	_
139-24	23121-23122	:	_
139-25	23123-23163	//www.nitrc.org/projects/artifact_detect	_
139-26	23164-23165	)	_
139-27	23166-23168	to	_
139-28	23169-23175	detect	_
139-29	23176-23183	outlier	_
139-30	23184-23191	volumes	_
139-31	23192-23193	.	_

Text=The ART software identifies outliers if the normalized z-score of the global mean intensity of a volume exceed a specified threshold and/or if extensive composite movement from a preceding image occurs.
140-1	23194-23197	The	_
140-2	23198-23201	ART	_
140-3	23202-23210	software	_
140-4	23211-23221	identifies	_
140-5	23222-23230	outliers	_
140-6	23231-23233	if	_
140-7	23234-23237	the	_
140-8	23238-23248	normalized	_
140-9	23249-23256	z-score	_
140-10	23257-23259	of	_
140-11	23260-23263	the	_
140-12	23264-23270	global	_
140-13	23271-23275	mean	_
140-14	23276-23285	intensity	_
140-15	23286-23288	of	_
140-16	23289-23290	a	_
140-17	23291-23297	volume	_
140-18	23298-23304	exceed	_
140-19	23305-23306	a	_
140-20	23307-23316	specified	_
140-21	23317-23326	threshold	_
140-22	23327-23333	and/or	_
140-23	23334-23336	if	_
140-24	23337-23346	extensive	_
140-25	23347-23356	composite	_
140-26	23357-23365	movement	_
140-27	23366-23370	from	_
140-28	23371-23372	a	_
140-29	23373-23382	preceding	_
140-30	23383-23388	image	_
140-31	23389-23395	occurs	_
140-32	23396-23397	.	_

Text=Preprocessing will be conducted with the standard procedure analysis including slice time correction, realignment, co-registration, normalizing, smoothing.
141-1	23398-23411	Preprocessing	_
141-2	23412-23416	will	_
141-3	23417-23419	be	_
141-4	23420-23429	conducted	_
141-5	23430-23434	with	_
141-6	23435-23438	the	_
141-7	23439-23447	standard	_
141-8	23448-23457	procedure	_
141-9	23458-23466	analysis	_
141-10	23467-23476	including	_
141-11	23477-23482	slice	_
141-12	23483-23487	time	_
141-13	23488-23498	correction	_
141-14	23499-23500	,	_
141-15	23501-23512	realignment	_
141-16	23513-23514	,	_
141-17	23515-23530	co-registration	_
141-18	23531-23532	,	_
141-19	23533-23544	normalizing	_
141-20	23545-23546	,	_
141-21	23547-23556	smoothing	_
141-22	23557-23558	.	_

Text=Statistical analysis on the first (individual) level will be performed by modeling the different conditions using boxcar functions convoluted with the hemodynamic response function as explanatory variables within the context of the general linear model (GLM) on a voxel-by-voxel basis.
142-1	23559-23570	Statistical	_
142-2	23571-23579	analysis	_
142-3	23580-23582	on	_
142-4	23583-23586	the	_
142-5	23587-23592	first	_
142-6	23593-23594	(	_
142-7	23595-23605	individual	_
142-8	23606-23607	)	_
142-9	23608-23613	level	_
142-10	23614-23618	will	_
142-11	23619-23621	be	_
142-12	23622-23631	performed	_
142-13	23632-23634	by	_
142-14	23635-23643	modeling	_
142-15	23644-23647	the	_
142-16	23648-23657	different	_
142-17	23658-23668	conditions	_
142-18	23669-23674	using	_
142-19	23675-23681	boxcar	_
142-20	23682-23691	functions	_
142-21	23692-23702	convoluted	_
142-22	23703-23707	with	_
142-23	23708-23711	the	_
142-24	23712-23723	hemodynamic	_
142-25	23724-23732	response	_
142-26	23733-23741	function	_
142-27	23742-23744	as	_
142-28	23745-23756	explanatory	_
142-29	23757-23766	variables	_
142-30	23767-23773	within	_
142-31	23774-23777	the	_
142-32	23778-23785	context	_
142-33	23786-23788	of	_
142-34	23789-23792	the	_
142-35	23793-23800	general	_
142-36	23801-23807	linear	_
142-37	23808-23813	model	_
142-38	23814-23815	(	_
142-39	23816-23819	GLM	_
142-40	23820-23821	)	_
142-41	23822-23824	on	_
142-42	23825-23826	a	_
142-43	23827-23841	voxel-by-voxel	_
142-44	23842-23847	basis	_
142-45	23848-23849	.	_

Text=Connectivity fMRI analysis Task and resting state fMRI data will additionally be analyzed by connectivity approaches.
143-1	23850-23862	Connectivity	_
143-2	23863-23867	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
143-3	23868-23876	analysis	_
143-4	23877-23881	Task	_
143-5	23882-23885	and	_
143-6	23886-23893	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
143-7	23894-23899	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
143-8	23900-23904	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
143-9	23905-23909	data	_
143-10	23910-23914	will	_
143-11	23915-23927	additionally	_
143-12	23928-23930	be	_
143-13	23931-23939	analyzed	_
143-14	23940-23942	by	_
143-15	23943-23955	connectivity	_
143-16	23956-23966	approaches	_
143-17	23967-23968	.	_

Text=To account for physiological and movement artifacts which strongly introduce artificial correlations into the data, heart beat and respiration will be monitored during scanning and physiological correction will be conducted with the software Aztec.
144-1	23969-23971	To	_
144-2	23972-23979	account	_
144-3	23980-23983	for	_
144-4	23984-23997	physiological	_
144-5	23998-24001	and	_
144-6	24002-24010	movement	_
144-7	24011-24020	artifacts	_
144-8	24021-24026	which	_
144-9	24027-24035	strongly	_
144-10	24036-24045	introduce	_
144-11	24046-24056	artificial	_
144-12	24057-24069	correlations	_
144-13	24070-24074	into	_
144-14	24075-24078	the	_
144-15	24079-24083	data	_
144-16	24084-24085	,	_
144-17	24086-24091	heart	_
144-18	24092-24096	beat	_
144-19	24097-24100	and	_
144-20	24101-24112	respiration	_
144-21	24113-24117	will	_
144-22	24118-24120	be	_
144-23	24121-24130	monitored	_
144-24	24131-24137	during	_
144-25	24138-24146	scanning	_
144-26	24147-24150	and	_
144-27	24151-24164	physiological	_
144-28	24165-24175	correction	_
144-29	24176-24180	will	_
144-30	24181-24183	be	_
144-31	24184-24193	conducted	_
144-32	24194-24198	with	_
144-33	24199-24202	the	_
144-34	24203-24211	software	_
144-35	24212-24217	Aztec	_
144-36	24218-24219	.	_

Text=Afterwards, images are preprocessed as described before by SPM 12.
145-1	24220-24230	Afterwards	_
145-2	24231-24232	,	_
145-3	24233-24239	images	_
145-4	24240-24243	are	_
145-5	24244-24256	preprocessed	_
145-6	24257-24259	as	_
145-7	24260-24269	described	_
145-8	24270-24276	before	_
145-9	24277-24279	by	_
145-10	24280-24283	SPM	_
145-11	24284-24286	12	_
145-12	24287-24288	.	_

Text=Task-dependent connectivity will be examined by functional connectivity and psychophysiological interaction analyses.
146-1	24289-24303	Task-dependent	_
146-2	24304-24316	connectivity	_
146-3	24317-24321	will	_
146-4	24322-24324	be	_
146-5	24325-24333	examined	_
146-6	24334-24336	by	_
146-7	24337-24347	functional	_
146-8	24348-24360	connectivity	_
146-9	24361-24364	and	_
146-10	24365-24384	psychophysiological	_
146-11	24385-24396	interaction	_
146-12	24397-24405	analyses	_
146-13	24406-24407	.	_

Text=Resting state data will be examined by conventional as well as dynamic functional connectivity analysis.
147-1	24408-24415	Resting	_
147-2	24416-24421	state	_
147-3	24422-24426	data	_
147-4	24427-24431	will	_
147-5	24432-24434	be	_
147-6	24435-24443	examined	_
147-7	24444-24446	by	_
147-8	24447-24459	conventional	_
147-9	24460-24462	as	_
147-10	24463-24467	well	_
147-11	24468-24470	as	_
147-12	24471-24478	dynamic	_
147-13	24479-24489	functional	_
147-14	24490-24502	connectivity	_
147-15	24503-24511	analysis	_
147-16	24512-24513	.	_

Text=Analyses in both task and rest will be conducted in a hypothesis-driven network-specific as well as more exploratory whole-brain manner.
148-1	24514-24522	Analyses	_
148-2	24523-24525	in	_
148-3	24526-24530	both	_
148-4	24531-24535	task	_
148-5	24536-24539	and	_
148-6	24540-24544	rest	_
148-7	24545-24549	will	_
148-8	24550-24552	be	_
148-9	24553-24562	conducted	_
148-10	24563-24565	in	_
148-11	24566-24567	a	_
148-12	24568-24585	hypothesis-driven	_
148-13	24586-24602	network-specific	_
148-14	24603-24605	as	_
148-15	24606-24610	well	_
148-16	24611-24613	as	_
148-17	24614-24618	more	_
148-18	24619-24630	exploratory	_
148-19	24631-24642	whole-brain	_
148-20	24643-24649	manner	_
148-21	24650-24651	.	_

Text=The whole-brain results will be further analyzed by graph theoretical tools to elucidate relevant changes in functional network topology.
149-1	24652-24655	The	_
149-2	24656-24667	whole-brain	_
149-3	24668-24675	results	_
149-4	24676-24680	will	_
149-5	24681-24683	be	_
149-6	24684-24691	further	_
149-7	24692-24700	analyzed	_
149-8	24701-24703	by	_
149-9	24704-24709	graph	_
149-10	24710-24721	theoretical	_
149-11	24722-24727	tools	_
149-12	24728-24730	to	_
149-13	24731-24740	elucidate	_
149-14	24741-24749	relevant	_
149-15	24750-24757	changes	_
149-16	24758-24760	in	_
149-17	24761-24771	functional	_
149-18	24772-24779	network	_
149-19	24780-24788	topology	_
149-20	24789-24790	.	_

Text=Data management The project data will be saved on the central server of the institute.
150-1	24791-24795	Data	_
150-2	24796-24806	management	_
150-3	24807-24810	The	_
150-4	24811-24818	project	_
150-5	24819-24823	data	_
150-6	24824-24828	will	_
150-7	24829-24831	be	_
150-8	24832-24837	saved	_
150-9	24838-24840	on	_
150-10	24841-24844	the	_
150-11	24845-24852	central	_
150-12	24853-24859	server	_
150-13	24860-24862	of	_
150-14	24863-24866	the	_
150-15	24867-24876	institute	_
150-16	24877-24878	.	_

Text=The IT department professionally maintains the server; thereby a daily backup of all data is performed.
151-1	24879-24882	The	_
151-2	24883-24885	IT	_
151-3	24886-24896	department	_
151-4	24897-24911	professionally	_
151-5	24912-24921	maintains	_
151-6	24922-24925	the	_
151-7	24926-24932	server	_
151-8	24933-24934	;	_
151-9	24935-24942	thereby	_
151-10	24943-24944	a	_
151-11	24945-24950	daily	_
151-12	24951-24957	backup	_
151-13	24958-24960	of	_
151-14	24961-24964	all	_
151-15	24965-24969	data	_
151-16	24970-24972	is	_
151-17	24973-24982	performed	_
151-18	24983-24984	.	_

Text=Additionally, a network independent backup will be saved on local hard drive.
152-1	24985-24997	Additionally	_
152-2	24998-24999	,	_
152-3	25000-25001	a	_
152-4	25002-25009	network	_
152-5	25010-25021	independent	_
152-6	25022-25028	backup	_
152-7	25029-25033	will	_
152-8	25034-25036	be	_
152-9	25037-25042	saved	_
152-10	25043-25045	on	_
152-11	25046-25051	local	_
152-12	25052-25056	hard	_
152-13	25057-25062	drive	_
152-14	25063-25064	.	_

Text=Experimental data, as well as questionnaires will be saved in a pseudonymized form, separately from consent forms that contain the names of the participants.
153-1	25065-25077	Experimental	_
153-2	25078-25082	data	_
153-3	25083-25084	,	_
153-4	25085-25087	as	_
153-5	25088-25092	well	_
153-6	25093-25095	as	_
153-7	25096-25110	questionnaires	_
153-8	25111-25115	will	_
153-9	25116-25118	be	_
153-10	25119-25124	saved	_
153-11	25125-25127	in	_
153-12	25128-25129	a	_
153-13	25130-25143	pseudonymized	_
153-14	25144-25148	form	_
153-15	25149-25150	,	_
153-16	25151-25161	separately	_
153-17	25162-25166	from	_
153-18	25167-25174	consent	_
153-19	25175-25180	forms	_
153-20	25181-25185	that	_
153-21	25186-25193	contain	_
153-22	25194-25197	the	_
153-23	25198-25203	names	_
153-24	25204-25206	of	_
153-25	25207-25210	the	_
153-26	25211-25223	participants	_
153-27	25224-25225	.	_

Text=In addition, hard copy storage of reports, protocols, presentations or publication drafts will be realized.
154-1	25226-25228	In	_
154-2	25229-25237	addition	_
154-3	25238-25239	,	_
154-4	25240-25244	hard	_
154-5	25245-25249	copy	_
154-6	25250-25257	storage	_
154-7	25258-25260	of	_
154-8	25261-25268	reports	_
154-9	25269-25270	,	_
154-10	25271-25280	protocols	_
154-11	25281-25282	,	_
154-12	25283-25296	presentations	_
154-13	25297-25299	or	_
154-14	25300-25311	publication	_
154-15	25312-25318	drafts	_
154-16	25319-25323	will	_
154-17	25324-25326	be	_
154-18	25327-25335	realized	_
154-19	25336-25337	.	_

Text=All data will be pseudonymized using unique study codes, which will be used to code and file all electronic information.
155-1	25338-25341	All	_
155-2	25342-25346	data	_
155-3	25347-25351	will	_
155-4	25352-25354	be	_
155-5	25355-25368	pseudonymized	_
155-6	25369-25374	using	_
155-7	25375-25381	unique	_
155-8	25382-25387	study	_
155-9	25388-25393	codes	_
155-10	25394-25395	,	_
155-11	25396-25401	which	_
155-12	25402-25406	will	_
155-13	25407-25409	be	_
155-14	25410-25414	used	_
155-15	25415-25417	to	_
155-16	25418-25422	code	_
155-17	25423-25426	and	_
155-18	25427-25431	file	_
155-19	25432-25435	all	_
155-20	25436-25446	electronic	_
155-21	25447-25458	information	_
155-22	25459-25460	.	_

Text=The key linking this code to participant identity will be stored in a secured file, access to this key is available only to designated members of the research team.
156-1	25461-25464	The	_
156-2	25465-25468	key	_
156-3	25469-25476	linking	_
156-4	25477-25481	this	_
156-5	25482-25486	code	_
156-6	25487-25489	to	_
156-7	25490-25501	participant	_
156-8	25502-25510	identity	_
156-9	25511-25515	will	_
156-10	25516-25518	be	_
156-11	25519-25525	stored	_
156-12	25526-25528	in	_
156-13	25529-25530	a	_
156-14	25531-25538	secured	_
156-15	25539-25543	file	_
156-16	25544-25545	,	_
156-17	25546-25552	access	_
156-18	25553-25555	to	_
156-19	25556-25560	this	_
156-20	25561-25564	key	_
156-21	25565-25567	is	_
156-22	25568-25577	available	_
156-23	25578-25582	only	_
156-24	25583-25585	to	_
156-25	25586-25596	designated	_
156-26	25597-25604	members	_
156-27	25605-25607	of	_
156-28	25608-25611	the	_
156-29	25612-25620	research	_
156-30	25621-25625	team	_
156-31	25626-25627	.	_

Text=These researchers will have unrestricted access to all study data.
157-1	25628-25633	These	_
157-2	25634-25645	researchers	_
157-3	25646-25650	will	_
157-4	25651-25655	have	_
157-5	25656-25668	unrestricted	_
157-6	25669-25675	access	_
157-7	25676-25678	to	_
157-8	25679-25682	all	_
157-9	25683-25688	study	_
157-10	25689-25693	data	_
157-11	25694-25695	.	_

Text=As mentioned above, anonymized data will be made available for re- or meta-analysis after request.
158-1	25696-25698	As	_
158-2	25699-25708	mentioned	_
158-3	25709-25714	above	_
158-4	25715-25716	,	_
158-5	25717-25727	anonymized	_
158-6	25728-25732	data	_
158-7	25733-25737	will	_
158-8	25738-25740	be	_
158-9	25741-25745	made	_
158-10	25746-25755	available	_
158-11	25756-25759	for	_
158-12	25760-25763	re-	_
158-13	25764-25766	or	_
158-14	25767-25780	meta-analysis	_
158-15	25781-25786	after	_
158-16	25787-25794	request	_
158-17	25795-25796	.	_

